Any feedback?
Information on EC 3.1.4.4 - phospholipase D
for references in articles please use BRENDA:EC3.1.4.4Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.1.4.4 phospholipase DIUBMB Comments
Also acts on other phosphatidyl esters.
Specify your search results
Word Map
- 3.1.4.4
-
phosphatidic
- diacylglycerol
- pkc
-
liposomal
- doxorubicin
- agonist
-
pegylated
-
phorbol
- phospholipases
-
transphosphatidylation
- 12-myristate
-
adp-ribosylation
- 13-acetate
- pertussis
-
phosphohydrolase
-
arachidonic
- propranolol
- phosphoinositide
-
gtp-binding
- fmlp
-
prelabeled
- anandamide
- rhoa
- 1-butanol
-
endocannabinoids
- staurosporine
-
lysophosphatidic
- pc-plc
-
phosphatidylcholine-specific
-
latissimus
- diglyceride
- pkcalpha
-
phosphatidylinositol-specific
- pseudotuberculosis
- 1,2-diacylglycerol
- arf6
- cannabinoids
-
fmet-leu-phe
-
listening
-
fmlp-stimulated
-
platinum-resistant
- analysis
-
phosphoinositide-specific
- gtpgammas
- synthesis
-
3hcholine
-
hand-foot
-
platinum-sensitive
-
fmlp-induced
- lymphadenitis
- medicine
-
ptdins4,5p2
- molecular biology
- 5-kinase
- agriculture
- biotechnology
The enzyme appears in viruses and cellular organisms
Synonyms
pld, phospholipase d, nape-pld, phospholipase d1, dermonecrotic toxin, phospholipase d2, pc-pld, pldalpha, rpld1, spo14, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
AtPLDalpha1
-
-
-
-
AtPLDalpha2
-
-
-
-
AtPLDbeta1
-
-
-
-
AtPLDbeta2
-
-
-
-
AtPLDdelta
-
-
-
-
AtPLDepsilon
-
-
-
-
AtPLDgamma1
-
-
-
-
AtPLDgamma2
-
-
-
-
AtPLDgamma3
-
-
-
-
AtPLDp1
-
-
-
-
AtPLDp2
-
-
-
-
AtPLDzeta
-
-
-
-
choline phosphatase
-
-
-
-
hPLD1
-
-
-
-
hPLD2
-
-
-
-
lecithinase D
-
-
-
-
lipophosphodiesterase II
-
-
-
-
Meiosis-specific sporulation protein SPO14
-
-
-
-
mPLD1
-
-
-
-
mPLD2
-
-
-
-
Phosphatidylcholine-hydrolyzing phospholipase D1
-
-
-
-
Phosphatidylcholine-hydrolyzing phospholipase D2
-
-
-
-
Phospholipase D1 PHOX and PX containing domain
-
-
-
-
Phospholipase D2 PHOX and PX containing domain
-
-
-
-
PLD
-
-
-
-
PLD delta
-
-
-
-
PLD epsilon
-
-
-
-
PLD zeta
-
-
-
-
PLD1C
-
-
-
-
PLDalpha
-
-
-
-
PLDalpha3
-
-
-
-
PLDbeta
-
-
-
-
PLDdelta1
-
-
-
-
PLDzeta1
-
-
-
-
PLDzeta2
-
-
-
-
rPLD1
-
-
-
-
rPLD2
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of phosphoric ester
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
-
-, -, -
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
phosphatidylcholine phosphatidohydrolase
Also acts on other phosphatidyl esters.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9001-87-0
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
Endocannabinoid System in First Trimester Placenta: Low FAAH and High CB1 Expression Characterize Spontaneous Miscarriage.
Abscess
Distribution of PLD and FagA, B, C and D genes in Corynebacterium pseudotuberculosis isolates from sheep and goats with caseus lymphadenitis.
Abscess
In vivo and in vitro expression of five genes involved in Corynebacterium pseudotuberculosis virulence.
Abscess
Unusual case of pyogenic spondylodiscitis, vertebral osteomyelitis and bilateral psoas abscesses after acupuncture: diagnosis and treatment with interventional management.
Acquired Immunodeficiency Syndrome
Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection.
Acute Coronary Syndrome
Characterization of the serological response to phospholipase D protein of Chlamydophila pneumoniae in patients with acute coronary syndromes.
Acute Coronary Syndrome
Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications.
Acute Lung Injury
Phospholipase D isoforms differentially regulate leukocyte responses to acute lung injury.
Acute Lung Injury
Phospholipase D participates in H(2)O(2)-induced A549 alveolar epithelial cell migration.
Acute Lung Injury
Platycodin D attenuates acute lung injury by suppressing apoptosis and inflammation in vivo and in vitro.
Adenocarcinoma
A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and beta1-integrin point contact distribution.
Adenocarcinoma
Effect of Rho and ADP-ribosylation factor GTPases on phospholipase D activity in intact human adenocarcinoma A549 cells.
Adenocarcinoma
Overproduction of urokinase-type plasminogen activator is regulated by phospholipase D- and protein kinase C-dependent pathways in murine mammary adenocarcinoma cells.
Adenocarcinoma
Pancreatic ductal adenocarcinoma associated with Potter type III cystic disease.
Adenocarcinoma
Paxillin phosphorylation and complexing with Erk and FAK are regulated by PLD activity in MDA-MB-231 cells.
Adenocarcinoma
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer]
Adenocarcinoma
[Studies on the significance of PLD repair for radioresistance in human uterine adenocarcinoma cells]
Adenocarcinoma of Lung
Activation of phospholipase D by bradykinin and sphingosine 1-phosphate in A549 human lung adenocarcinoma cells via different GTP-binding proteins and protein kinase C delta signaling pathways.
Adenoviridae Infections
Enhancement of phospholipase D activity following baculovirus and adenovirus infection in Sf9 and COS-7 cells.
Adrenocortical Carcinoma
A role for phospholipase D in angiotensin II-induced protein kinase D activation in adrenal glomerulosa cell models.
Adrenocortical Carcinoma
AngII induces transient phospholipase D activity in the H295R glomerulosa cell model.
Adrenocortical Carcinoma
The Role of Calcium Influx Pathways in Phospholipase D Activation in Bovine Adrenal Glomerulosa Cells.
Adrenoleukodystrophy
Phospholipase D activity is altered in X-linked adrenoleukodystrophy heterozygous carriers, but not in hemizygous patients.
Agranulocytosis
[Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Alopecia
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
Alopecia
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
Alopecia
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Alopecia
Liposomal anthracycline administration and toxicity management: a nursing perspective.
Alopecia
Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Alopecia
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
Alopecia
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alopecia
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Alopecia
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Alopecia
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Alopecia
[Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Alzheimer Disease
Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits.
Alzheimer Disease
Intermolecular association between caspase-mediated cleavage fragments of phospholipase D1 protects against apoptosis.
Alzheimer Disease
Pharmacological effects of phosphatidylserine enzymatically synthesized from soybean lecithin on brain functions in rodents.
Alzheimer Disease
Phospholipase D functional ablation has a protective effect in an Alzheimer's disease Caenorhabditis elegans model.
Alzheimer Disease
Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons.
Alzheimer Disease
Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease.
Alzheimer Disease
Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer's disease patients.
Alzheimer Disease
Phospholipid metabolism in Alzheimer's disease and in a human cholinergic cell.
Alzheimer Disease
PLD3 is a neuronal lysosomal phospholipase D associated with ?-amyloid plaques and cognitive function in Alzheimer's disease.
Alzheimer Disease
Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients.
Alzheimer Disease
Suppressing aberrant phospholipase D1 signaling in 3xTg Alzheimer's disease mouse model promotes synaptic resilience.
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target.
Amyotrophic Lateral Sclerosis
Using Drosophila melanogaster To Discover Human Disease Genes: An Educational Primer for Use with "Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target".
Anaphylaxis
Modulation of human eosinophil polymorphonuclear leukocyte migration and function.
Anemia
Adult polycystic liver disease concomitant with severe anemia due to intracystic bleeding is indicated to liver transplantation: case report and review of literature.
Anemia
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Anemia
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Anemia
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin.
Anemia
The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Anemia
[Risk factors for pleural lung disease in children with juvenile idiopathic arthritis].
Anemia, Hemolytic
Early experience with the Occlutech PLD occluder for mitral paravalvar leak closure through a hybrid transapical approach.
Aneurysm
Early Limb Reperfusion Using Routinely Preloaded Fenestrated Stent-graft Designs for Complex Endovascular Aortic Procedures.
Aneurysm
Sequential changes of arterial spin-labeling perfusion MR images with dual postlabeling delay following reconstructive surgery for giant internal carotid artery aneurysm.
Angioedema
Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
Anosmia
The Phospholipase D2 Knock Out Mouse Has Ectopic Purkinje Cells and Suffers from Early Adult-Onset Anosmia.
Arthritis
Phospholipase D1 has a pivotal role in interleukin-1?-driven chronic autoimmune arthritis through regulation of NF-?B, hypoxia-inducible factor 1?, and FoxO3a.
Arthritis, Experimental
Targeting of Phospholipase D1 Ameliorates Collagen-Induced Arthritis via Modulation of Treg and Th17 Cell Imbalance and Suppression of Osteoclastogenesis.
Arthritis, Rheumatoid
IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis.
Arthritis, Rheumatoid
Phospholipase D enzymes facilitate IL-17- and TNF?-induced expression of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASF).
Asthma
Human recombinant PLD2 can repress p65 activity of guinea pigs of chronic asthma in vivo.
Asthma
Measuring productivity loss days in asthma patients. The Pharmacy Medication Monitoring Program and Advisory Board.
Asthma
Platycodin D Attenuates Airway Inflammation in a Mouse Model of Allergic Asthma by Regulation NF-?B Pathway.
Asthma
Platycodin D attenuates airway inflammation via suppression Th2 transcription factor in a murine model of acute asthma.
Astrocytoma
Functional coupling of the NK1 tachykinin receptor to phospholipase D in chinese hamster ovary cells and astrocytoma cells.
Astrocytoma
Mastoparan-induced phosphatidylcholine hydrolysis by phospholipase D activation in human astrocytoma cells.
Astrocytoma
Phospholipase C, protein kinase C, Ca2+/calmodulin-dependent protein kinase II, and redox state are involved in epigallocatechin gallate-induced phospholipase D activation in human astroglioma cells.
Astrocytoma
Phospholipase D is activated and phosphorylated by casein kinase-II in human U87 astroglioma cells.
Astrocytoma
Phospholipase D isozymes mediate epigallocatechin gallate-induced cyclooxygenase-2 expression in astrocyte cells.
Astrocytoma
Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease.
Astrocytoma
Rapid heterologous desensitization of muscarinic and thrombin receptor-mediated phospholipase D activation.
Astrocytoma
Role of phospholipase D signaling in ethanol-induced inhibition of carbachol-stimulated DNA synthesis of 1321N1 astrocytoma cells.
Astrocytoma
Signal transduction mechanisms involved in the antiproliferative effects of ethanol in glial cells.
Astrocytoma
Up-regulation of cyclooxygenase-2 by cobalt chloride-induced hypoxia is mediated by phospholipase D isozymes in human astroglioma cells.
Ataxia Telangiectasia
Defective recovery from potentially lethal damage in some human fibroblast cell strains.
Ataxia Telangiectasia
Deficient recovery from potentially lethal damage in some gamma-irradiated human fibroblast cell strains.
Atherosclerosis
ANG II stimulates phospholipase D through PKCzeta activation in VSMC: implications in adhesion, spreading, and hypertrophy.
Atherosclerosis
Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis.
Atherosclerosis
Lysophosphatidylcholine stimulates phospholipase D activity in mouse peritoneal macrophages.
Atherosclerosis
Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis.
Atherosclerosis
Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages.
Atherosclerosis
Targeting Phospholipase D Genetically and Pharmacologically for Studying Leukocyte Function.
Atrial Fibrillation
Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial.
Autoimmune Diseases
LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.
Autoimmune Diseases
Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon.
Autoimmune Diseases
Targeting of Phospholipase D1 Ameliorates Collagen-Induced Arthritis via Modulation of Treg and Th17 Cell Imbalance and Suppression of Osteoclastogenesis.
Bacterial Infections
Discovery of Desketoraloxifene Analogues as Inhibitors of Mammalian, Pseudomonas aeruginosa, and NAPE Phospholipase D Enzymes.
Bardet-Biedl Syndrome
Bardet-Biedl syndrome 3 protein promotes ciliary exit of the signaling protein phospholipase D via the BBSome.
Blister
Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
Blister
Reversible bleb formation in mast cells stimulated with antigen is Ca2+-calmodulin -dependent and bleb size is regulated by ARF6.
Bone Cysts
Laparoscopic management of symptomatic nonparasitic cysts of the liver. Indications and results.
Bone Resorption
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida.
Bone Resorption
Swine Atrophic Rhinitis Caused by Pasteurella multocida Toxin and Bordetella Dermonecrotic Toxin.
Brain Diseases
Bordetella Dermonecrotic Toxin Is a Neurotropic Virulence Factor That Uses CaV3.1 as the Cell Surface Receptor.
Brain Infarction
Enzymatic Activity Is Not Required for Phospholipase D Mediated TNF-? Regulation and Myocardial Healing.
Brain Infarction
Pharmacological inhibition of phospholipase d protects mice from occlusive thrombus formation and ischemic stroke--brief report.
Brain Ischemia
Brain ischemia decreases phosphatidylcholine-phospholipase D but not phosphatidylinositol-phospholipase C in rats.
Brain Neoplasms
Pegylated Liposomal Doxorubicin Is an Active Agent for Chemotherapy-Resistant Choriocarcinoma: A Report of Two Cases.
Brain Neoplasms
Pulsed-wave low-dose ultrasound hyperthermia selectively enhances nanodrug delivery and improves antitumor efficacy for brain metastasis of breast cancer.
Brain Neoplasms
Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Breast Neoplasms
A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation.
Breast Neoplasms
A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells.
Breast Neoplasms
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer.
Breast Neoplasms
A Repertoire of MicroRNAs Regulates Cancer Cell Starvation by Targeting Phospholipase D in a Feedback Loop That Operates Maximally in Cancer Cells.
Breast Neoplasms
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial.
Breast Neoplasms
Alternative phospholipase D/mTOR survival signal in human breast cancer cells.
Breast Neoplasms
Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells.
Breast Neoplasms
Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Breast Neoplasms
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
Breast Neoplasms
Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers.
Breast Neoplasms
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
Breast Neoplasms
Down-regulation of MicroRNAs (MiRs) 203, 887, 3619 and 182 Prevents Vimentin-triggered, Phospholipase D (PLD)-mediated Cancer Cell Invasion.
Breast Neoplasms
Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency.
Breast Neoplasms
Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Breast Neoplasms
Fulminant liver failure in a patient affected by polycystic liver disease and liver metastases from breast carcinoma.
Breast Neoplasms
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.
Breast Neoplasms
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.
Breast Neoplasms
How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD.
Breast Neoplasms
Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Breast Neoplasms
Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
Breast Neoplasms
Increased phospholipase D activity in multidrug resistant breast cancer cells.
Breast Neoplasms
Inhibition of phorbol ester-stimulated phospholipase D activity by chronic tamoxifen treatment in breast cancer cells.
Breast Neoplasms
Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.
Breast Neoplasms
Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors.
Breast Neoplasms
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-Trial).
Breast Neoplasms
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells.
Breast Neoplasms
Linoleic acid induces secretion of extracellular vesicles from MDA-MB-231 breast cancer cells that mediate cellular processes involved with angiogenesis in HUVECs.
Breast Neoplasms
Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors.
Breast Neoplasms
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Breast Neoplasms
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
Breast Neoplasms
Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report.
Breast Neoplasms
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Breast Neoplasms
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Breast Neoplasms
Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D.
Breast Neoplasms
Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells.
Breast Neoplasms
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Breast Neoplasms
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Breast Neoplasms
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Breast Neoplasms
Paxillin phosphorylation and complexing with Erk and FAK are regulated by PLD activity in MDA-MB-231 cells.
Breast Neoplasms
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation study.
Breast Neoplasms
Pegylated liposomal doxorubicin (Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients previously treated with anthracyclines.
Breast Neoplasms
Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
Breast Neoplasms
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Breast Neoplasms
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Breast Neoplasms
Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Breast Neoplasms
Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified.
Breast Neoplasms
Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Breast Neoplasms
Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: a case report.
Breast Neoplasms
Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Breast Neoplasms
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Breast Neoplasms
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Breast Neoplasms
Pharmacokinetics. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in chinese patients with breast tumours.
Breast Neoplasms
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
Breast Neoplasms
Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
Breast Neoplasms
Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines.
Breast Neoplasms
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
Breast Neoplasms
Phorbol ester selectively stimulates the phospholipase D-mediated hydrolysis of phosphatidylethanolamine in multidrug-resistant MCF-7 human breast carcinoma cells.
Breast Neoplasms
Phorbol ester stimulation of phosphatidylcholine synthesis requires expression of both protein kinase C-alpha and phospholipase D.
Breast Neoplasms
Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized Receptor.
Breast Neoplasms
Phospholipase C-protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis.
Breast Neoplasms
Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model.
Breast Neoplasms
Phospholipase D confers rapamycin resistance in human breast cancer cells.
Breast Neoplasms
Phospholipase D couples survival and migration signals in stress response of human cancer cells.
Breast Neoplasms
Phospholipase D inhibitor enhances radiosensitivity of breast cancer cells.
Breast Neoplasms
Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells.
Breast Neoplasms
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.
Breast Neoplasms
Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.
Breast Neoplasms
Phospholipase D1 and choline kinase-? are interactive targets in breast cancer.
Breast Neoplasms
Phospholipid-modified upconversion nanoprobe for ratiometric fluorescence detection and imaging of phospholipase D in cell lysate and in living cells.
Breast Neoplasms
Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFkappaB signaling pathway and enhances invasion of breast cancer cells.
Breast Neoplasms
PLD-Specific Small-Molecule Inhibitors Decrease Tumor-Associated Macrophages and Neutrophils Infiltration in Breast Tumors and Lung and Liver Metastases.
Breast Neoplasms
PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas.
Breast Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Breast Neoplasms
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Breast Neoplasms
Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Breast Neoplasms
Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
Breast Neoplasms
Role of phospholipase D in migration and invasion induced by linoleic acid in breast cancer cells.
Breast Neoplasms
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Breast Neoplasms
SCD1 activity promotes cell migration via a PLD-mTOR pathway in the MDA-MB-231 triple-negative breast cancer cell line.
Breast Neoplasms
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Breast Neoplasms
Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Breast Neoplasms
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.
Breast Neoplasms
Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
Breast Neoplasms
Tamoxifen stimulates phospholipase D activity by an estrogen receptor-independent mechanism.
Breast Neoplasms
Target-controlled gating liposome "off-on" cascade amplification for sensitive and accurate detection of phospholipase D in breast cancer cells with a low-background signal.
Breast Neoplasms
Temporal production of the signaling lipid phosphatidic acid by phospholipase D2 determines the output of extracellular signal-regulated kinase signaling in cancer cells.
Breast Neoplasms
The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan.
Breast Neoplasms
The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells.
Breast Neoplasms
Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells.
Breast Neoplasms
Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study.
Breast Neoplasms
[Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay.
Carcinogenesis
alpha(1)-Adrenergic receptor stimulation of cell motility requires phospholipase D-mediated extracellular signal-regulated kinase activation.
Carcinogenesis
Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer.
Carcinogenesis
Autoregulation of phospholipase D activity is coupled to selective induction of phospholipase D1 expression to promote invasion of breast cancer cells.
Carcinogenesis
Caffeic acid phenethyl ester downregulates phospholipase D1 via direct binding and inhibition of NF?B transactivation.
Carcinogenesis
Enhanced levels of oleate-dependent and Arf-dependent phospholipase D isoforms in experimental colon cancer.
Carcinogenesis
HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Carcinogenesis
Increased phospholipase D activity contributes to tumorigenesis in prostate cancer cell models.
Carcinogenesis
Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
Carcinogenesis
Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D.
Carcinogenesis
Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts.
Carcinogenesis
Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways.
Carcinogenesis
Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells.
Carcinogenesis
Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.
Carcinogenesis
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Carcinogenesis
Plant phospholipase D mining unravels new conserved residues important for catalytic activity.
Carcinogenesis
Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells.
Carcinogenesis
RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Carcinogenesis
Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NF?B and suppresses invasion of gastric cancer cells.
Carcinogenesis
Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.
Carcinogenesis
Selective down-regulation of protein kinase c-epsilon by carcinogens does not prevent stimulation of phospholipase D by phorbol ester and platelet-derived growth factor.
Carcinogenesis
Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling ?-catenin signaling in cancer-initiating cells.
Carcinogenesis
Transcriptional repression of cyclin-dependent kinase inhibitor p21 gene by phospholipase D1 and D2.
Carcinogenesis
Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells.
Carcinoma
A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Carcinoma
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Carcinoma
AQP3 small interfering RNA and PLD2 small interfering RNA inhibit the proliferation and promote the apoptosis of squamous cell carcinoma.
Carcinoma
Efficient Prevention Strategy against the Development of a Palmar-Plantar Erythrodysesthesia during Chemotherapy.
Carcinoma
Enhancement of phospholipase D activity by overexpression of amyloid precursor protein in P19 mouse embryonic carcinoma cells.
Carcinoma
Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme.
Carcinoma
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma.
Carcinoma
G0 cell cycle arrest alone is insufficient for enabling the repair of ionizing radiation-induced potentially lethal damage.
Carcinoma
Induction of the early response protein EGR-1 in human tumour cells after ionizing radiation is correlated with a reduction of repair of lethal lesions and an increase of repair of sublethal lesions.
Carcinoma
Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
Carcinoma
Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors.
Carcinoma
MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma.
Carcinoma
MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/?-catenin pathway by targeting phospholipase D1.
Carcinoma
Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience.
Carcinoma
Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Carcinoma
Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.
Carcinoma
Pharmacokinetics of Pegylated Liposomal Doxorubicin Administered by Intraoperative Hyperthermic Intraperitoneal Chemotherapy to Patients with Advanced Ovarian Cancer and Peritoneal Carcinomatosis.
Carcinoma
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Carcinoma
Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Carcinoma
Phospholipase D mRNA expression and clinical role in high-grade serous carcinoma.
Carcinoma
Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin.
Carcinoma
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Carcinoma
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Carcinoma
Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling ?-catenin signaling in cancer-initiating cells.
Carcinoma
The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
Carcinoma
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
Carcinoma, Ehrlich Tumor
The importance of G1/S-border and mitosis in the fixation of potentially lethal damage.
Carcinoma, Ehrlich Tumor
The influence of PLD repair on the induction frequency of 6-thioguanine resistant mutants in Ehrlich ascites tumour cells after exposure to X-rays and ultraviolet light.
Carcinoma, Embryonal
Retinoic acid-induced differentiation into astrocytes and glutamatergic neurons is associated with expression of functional and activable phospholipase D.
Carcinoma, Hepatocellular
Coenzyme Q10 attenuates rat hepatocarcinogenesis via the reduction of CD59 expression and phospholipase D activity.
Carcinoma, Hepatocellular
Detection of nanocarrier potentiation on drug induced phospholipidosis in cultured cells and primary hepatocyte spheroids by high content imaging and analysis.
Carcinoma, Hepatocellular
From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.
Carcinoma, Hepatocellular
Important roles of glycosylphosphatidylinositol (GPI)-specific phospholipase D and some GPI-anchored proteins in the pathogenesis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors.
Carcinoma, Hepatocellular
Nuclear ADP-ribosylation factor (ARF)- and oleate-dependent phospholipase D (PLD) in rat liver cells. Increases of ARF-dependent PLD activity in regenerating liver cells.
Carcinoma, Hepatocellular
Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma.
Carcinoma, Hepatocellular
Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.
Carcinoma, Hepatocellular
Therapeutic inhibition of phospholipase D1 suppresses hepatocellular carcinoma.
Carcinoma, Hepatocellular
[Effect of overexpression of glycosylphosphatidylinositol-specific phospholipase D on biological character of hepatocellular carcinoma cell line HepG2.]
Carcinoma, Non-Small-Cell Lung
A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Carcinoma, Ovarian Epithelial
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Carcinoma, Ovarian Epithelial
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Carcinoma, Ovarian Epithelial
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Carcinoma, Ovarian Epithelial
Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
Carcinoma, Ovarian Epithelial
Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors.
Carcinoma, Ovarian Epithelial
Pegylated liposomal Doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Carcinoma, Ovarian Epithelial
Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Carcinoma, Ovarian Epithelial
Pegylated liposomal doxorubicin in the management of ovarian cancer.
Carcinoma, Ovarian Epithelial
Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin.
Carcinoma, Ovarian Epithelial
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Carcinoma, Ovarian Epithelial
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Carcinoma, Ovarian Epithelial
Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology.
Carcinoma, Ovarian Epithelial
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer]
Carcinoma, Renal Cell
Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin.
Carcinoma, Squamous Cell
AQP3 small interfering RNA and PLD2 small interfering RNA inhibit the proliferation and promote the apoptosis of squamous cell carcinoma.
Carcinoma, Squamous Cell
ATP- and EGF-stimulated phosphatidulinositol synthesis by two different pathways, phospholipase D and diacylglycerol kinase, in A-431 epidermoid carcinoma cells.
Carcinoma, Squamous Cell
Differential tyrosine phosphorylation of phospholipase D isozymes by hydrogen peroxide and the epidermal growth factor in A431 epidermoid carcinoma cells.
Carcinoma, Squamous Cell
Secretory phospholipase A(2) inhibits epidermal growth factor-induced receptor activation.
Carcinosarcoma
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET.
Cardiac Complexes, Premature
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
Cardiomegaly
Effects of norepinephrine and cardiotrophin-1 on phospholipase D activity and incorporation of myristic acid into phosphatidylcholine in rat heart.
Cardiomegaly
Mechanical stress stimulates phospholipase C activity and intracellular calcium ion levels in neonatal rat cardiomyocytes.
Cardiomegaly
Phospholipase D in rat myocardium: formation of lipid messengers and synergistic activation by G-protein and protein kinase C.
Cardiomegaly
Upregulation of phospholipase d expression and activation in ventricular pressure-overload hypertrophy.
Cardiomyopathies
Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer.
Cardiomyopathies
Oxidative stress and redox regulation of phospholipase D in myocardial disease.
Cardiotoxicity
Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
Cardiotoxicity
Analysis and evaluation of DRCOP scheme based on polyethylene glycol liposome doxorubicin in patients with diffuse large B-cell lymphoma.
Cardiotoxicity
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
Cardiotoxicity
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Cardiotoxicity
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
Cardiotoxicity
Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary?
Cardiotoxicity
Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cardiotoxicity
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Cardiotoxicity
High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies.
Cardiotoxicity
Liposomal anthracycline administration and toxicity management: a nursing perspective.
Cardiotoxicity
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Cardiotoxicity
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure.
Cardiotoxicity
Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600?mg/m2 in recurrent ovarian cancer.
Cardiotoxicity
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
Cardiotoxicity
Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
Cardiotoxicity
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Cardiotoxicity
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Cardiotoxicity
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Cardiotoxicity
Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Cardiotoxicity
Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Cardiotoxicity
Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study.
Cardiotoxicity
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Cardiotoxicity
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
Cardiotoxicity
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
Cardiotoxicity
Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
Cardiotoxicity
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
Cardiotoxicity
Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies.
Cardiotoxicity
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Cardiotoxicity
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Cardiotoxicity
Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature.
Cardiotoxicity
Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Cardiotoxicity
The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials.
Cardiotoxicity
Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Cardiotoxicity
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
Cardiotoxicity
Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Cardiotoxicity
Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study.
Cardiotoxicity
[Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Cardiotoxicity
[Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Cardiovascular Diseases
Calcium and calmodulin regulate mercury-induced phospholipase D activation in vascular endothelial cells.
Cardiovascular Diseases
Mercury activates vascular endothelial cell phospholipase D through thiols and oxidative stress.
Cardiovascular Diseases
N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of phospholipase D as a possible mechanism.
Cardiovascular Diseases
Structural Insights for Drugs Developed for Phospholipase D Enzymes.
Cataract
Synergism between phospholipase D2 and sorbitol accumulation in diabetic cataract formation through modulation of Na,K-ATPase activity and osmotic stress.
Cerebrospinal Fluid Rhinorrhea
Prevention of CSF rhinorrhea after transsphenoidal surgery by collagen fleece coated with fibrin sealant without autologous tissue graft or postoperative lumbar drainage.
Cerebrovascular Disorders
Arterial Spin Labeling Perfusion Magnetic Resonance Image with Dual Postlabeling Delay: A Correlative Study with Acetazolamide Loading (123)I-Iodoamphetamine Single-Photon Emission Computed Tomography.
Chagas Disease
Shedding light on lipid metabolism in Kinetoplastida: A phylogenetic analysis of phospholipase D protein homologs.
Chediak-Higashi Syndrome
Enhanced diacylglycerol production by phospholipase D activation is responsible for abnormal increase in concanavalin A cap formation in polymorphonuclear leukocytes from Chediak-Higashi syndrome (beige) mice.
Cholangiocarcinoma
Obstructive jaundice in polycystic liver disease related to coexisting cholangiocarcinoma.
Cholangitis
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Cholera
Activation of endothelial cell phospholipase D by sphingosine and sphingosine-1-phosphate.
Cholera
Activation of rat brain phospholipase D by ADP-ribosylation factors 1,5, and 6: separation of ADP-ribosylation factor-dependent and oleate-dependent enzymes.
Cholera
Arfaptin 1 inhibits ADP-ribosylation factor-dependent matrix metalloproteinase-9 secretion induced by phorbol ester in HT 1080 fibrosarcoma cells.
Cholera
Assays and properties of arfaptin 2 binding to Rac1 and ADP-ribosylation factors (Arfs).
Cholera
Characterization of a GDP dissociation inhibitory region of ADP-ribosylation factor domain protein ARD1.
Cholera
Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins.
Cholera
Different ARF domains are required for the activation of cholera toxin and phospholipase D.
Cholera
Effects of arfaptin 1 on guanine nucleotide-dependent activation of phospholipase D and cholera toxin by ADP-ribosylation factor.
Cholera
Guanine nucleotide-binding protein regulation of microsomal phospholipase D activity of canine cerebral cortex.
Cholera
Identification of lysosomal and Golgi localization signals in GAP and ARF domains of ARF domain protein 1.
Cholera
Interaction of the GTP-binding and GTPase-activating domains of ARD1 involves the effector region of the ADP-ribosylation factor domain.
Cholera
Muscarinic acetylcholine receptor regulates phosphatidylcholine phospholipase D in canine brain.
Cholera
Phospholipid- and GTP-dependent activation of cholera toxin and phospholipase D by human ADP-ribosylation factor-like protein 1 (HARL1).
Cholera
Regulation of phospholipase D and secretion in mast cells by protein kinase A and other protein kinases.
Cholera
Thapsigargin-induced secretion is dependent on activation of a cholera toxin-sensitive and phosphatidylinositol-3-kinase-regulated phospholipase D in a mast cell line.
Cholera
Thrombin stimulation of human endothelial cell phospholipase D activity. Regulation by phospholipase C, protein kinase C, and cyclic adenosine 3'5'-monophosphate.
Cholestasis
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Cholestasis, Intrahepatic
Phospholipase D2 mediates signaling by ATPase class I type 8B membrane 1.
Choline Deficiency
Dietary choline supplementation in pregnant rats increases hippocampal phospholipase D activity of the offspring.
Choriocarcinoma
Pegylated Liposomal Doxorubicin Is an Active Agent for Chemotherapy-Resistant Choriocarcinoma: A Report of Two Cases.
Choriocarcinoma
The comparison of pegylated liposomal doxorubicin and beta-carotene effects on JAR and JEG-3 choriocarcinoma human cell culture models
Choroidal Neovascularization
Choroidal neovascularization in acquired partial lipodystrophy.
Coffin-Lowry Syndrome
The Coffin-Lowry syndrome-associated protein RSK2 regulates neurite outgrowth through phosphorylation of phospholipase D1 (PLD1) and synthesis of phosphatidic acid.
Coinfection
Phospholipase gene expression during Paracoccidioides brasiliensis morphological transition and infection.
Colitis
Anti-inflammatory effects of Platycodin D on dextran sulfate sodium (DSS) induced colitis and E. coli Lipopolysaccharide (LPS) induced inflammation.
Colitis
Intestinal Epithelial Cell-Specific Deletion of PLD2 Alleviates DSS-Induced Colitis by Regulating Occludin.
Colitis
Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.
Colitis, Ulcerative
Anti-inflammatory effects of Platycodin D on dextran sulfate sodium (DSS) induced colitis and E. coli Lipopolysaccharide (LPS) induced inflammation.
Colonic Neoplasms
Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen.
Colonic Neoplasms
Enhanced levels of oleate-dependent and Arf-dependent phospholipase D isoforms in experimental colon cancer.
Colonic Neoplasms
Hypoxia-inducible factor 1-alpha up-regulates the expression of phospholipase D2 in colon cancer cells under hypoxic conditions.
Colonic Neoplasms
Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway.
Colonic Neoplasms
Mutated ras induced PLD1 gene expression through increased Sp1 transcription factor.
Colonic Neoplasms
Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells.
Colonic Neoplasms
Phospholipase D activation mediates growth and migration of colon cancer cells interacting with cancer-associated fibroblasts.
Colonic Neoplasms
Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells.
Colorectal Neoplasms
5-aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer.
Colorectal Neoplasms
Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer.
Colorectal Neoplasms
Catalytic inactivation of human phospholipase D2 by a naturally occurring Gly901Asp mutation.
Colorectal Neoplasms
Identification of differential proteins in colon cancer SW480 cells with HIF1-alpha silence by proteome analysis.
Colorectal Neoplasms
Increased activity and expression of phospholipase D2 in human colorectal cancer.
Colorectal Neoplasms
Inhibition of phospholipase D2 induces autophagy in colorectal cancer cells.
Colorectal Neoplasms
Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells.
Colorectal Neoplasms
Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/?-catenin and PI3K/Akt Signaling.
Colorectal Neoplasms
Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells.
Colorectal Neoplasms
Requirement of phospholipase D1 activity in H-RasV12-induced transformation.
Colorectal Neoplasms
Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling ?-catenin signaling in cancer-initiating cells.
Coronary Artery Disease
Postoperative liver dysfunction after total arch replacement combined with frozen elephant trunk implantation: incidence, risk factors and outcomes.
Coronary Occlusion
Phospholipase D plays a role in ischemic preconditioning in rabbit heart.
Cough
BspR/BtrA, an Anti-? Factor, Regulates the Ability of Bordetella bronchiseptica To Cause Cough in Rats.
Cough
Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
Coxsackievirus Infections
Reduction of phospholipase D activity during coxsackievirus infection.
Cysts
Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
Cysts
Cardiac compression of a hepatic cyst in polycystic liver disease: A rare cause of hemodynamic instability.
Cysts
Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series.
Cysts
Fatal liver cyst rupture in polycystic liver disease complicated with autosomal dominant polycystic kidney disease: A case report.
Cysts
IFT-A deficiency in juvenile mice impairs biliary development and exacerbates ADPKD liver disease.
Cysts
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Cysts
Laparoscopic management of symptomatic nonparasitic cysts of the liver. Indications and results.
Cysts
Laparoscopic treatment of nonparasitic liver cysts: adequate selection of patients and surgical technique.
Cysts
Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Cysts
Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
Cysts
Mutations in GANAB, Encoding the Glucosidase II? Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.
Cysts
New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
Cysts
Obstructive jaundice in a patient with polycystic liver disease complicated with polycystic kidney and polycystic lung: A case report.
Cysts
Obstructive jaundice in polycystic liver disease related to coexisting cholangiocarcinoma.
Cysts
Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.
Cysts
Polycystic Liver Disease with Huge Infected Cyst Displacing the Pancreas, Inferior Vena Cava and Right Kidney.
Cysts
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.
Cysts
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Cysts
Polycystic liver disease: multimodality imaging for complications and transplant evaluation.
Cysts
Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values.
Cysts
Results of percutaneous sclerotherapy and surgical treatment in patients with symptomatic simple liver cysts and polycystic liver disease.
Cysts
Severe polycystic liver diseases: hepatectomy or waiting for liver transplantation?: Two case reports.
Cysts
Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.
Cysts
Transarterial embolisation with bleomycin and N-butyl-2-cyanoacrylate -Lipiodol mixture for symptomatic polycystic liver disease: preliminary experience.
Cysts
Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up.
Deglutition Disorders
Oesophageal causes of dysphagia localised only to the pharynx: Implications for the suspected head and neck cancer pathway.
Dehydration
A transcriptional approach to unravel the connection between phospholipases A2 and D and ABA signal in citrus under water stress.
Dehydration
Abscisic acid modifies the changes in lipids brought about by water stress in the moss Atrichum androgynum.
Dehydration
Enzymatic activity and gene expression under water stress of phospholipase D in two cultivars of Vigna unguiculata L. Walp. differing in drought tolerance.
Dehydration
Involvement of a novel Arabidopsis phospholipase D, AtPLDdelta, in dehydration-inducible accumulation of phosphatidic acid in stress signalling.
Dehydration
Maintenance or collapse: responses of extraplastidic membrane lipid composition to desiccation in the resurrection plant Paraisometrum mileense.
Dehydration
Multiple PLDs required for high salinity and water deficit tolerance in plants.
Dehydration
Phospholipase D and phosphatidic acid signalling in plant response to drought and salinity.
Dehydration
The effect of phospholipase Dalpha3 on Arabidopsis response to hyperosmotic stress and glucose.
Dehydration
Water deficit triggers phospholipase D activity in the resurrection plant Craterostigma plantagineum.
Dementia
Enhancement of automated blood flow estimates (ENABLE) from arterial spin-labeled MRI.
Dementia
Phospholipase D1 regulates autophagic flux and clearance of ?-synuclein aggregates.
Diabetes Complications
Synergism between phospholipase D2 and sorbitol accumulation in diabetic cataract formation through modulation of Na,K-ATPase activity and osmotic stress.
Diabetes Mellitus
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Diabetes Mellitus
Characterization of prolidase activity using capillary electrophoresis with Tris(2,2'-bipyridyl)ruthenium(II) electrochemiluminescence detection and application to evaluate collagen degradation in diabetes mellitus.
Diabetes Mellitus, Type 2
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Diabetes Mellitus, Type 2
Discovery of Small Peptide Antagonists of PED/PEA15-D4? Interaction from Simplified Combinatorial Libraries.
Diabetic Nephropathies
High glucose-induced membrane translocation of PKC betaI is associated with Arf6 in glomerular mesangial cells.
Diabetic Retinopathy
High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy.
Diphtheria
Corynebacterium ulcerans Isolated from an Asymptomatic Dog Kept in an Animal Shelter in the Metropolitan Area of Rio de Janeiro, Brazil.
Diphtheria
Detection and virulence potential of a phospholipase D-negative Corynebacterium ulcerans from a concurrent diphtheria and infectious mononucleosis case.
Diphtheria
Isolation and characterization of Corynebacterium ulcerans from cephalic implants in macaques.
Diphtheria
Non-toxigenic Corynebacterium ulcerans sequence types 325 and 339 isolated from two dogs with ulcerative lesions in Italy.
Diphtheria
Outbreak with clonally related isolates of Corynebacterium ulcerans in a group of water rats.
Diphtheria
Strain-dependent arthritogenic potential of the zoonotic pathogen Corynebacterium ulcerans.
Discitis
Unusual case of pyogenic spondylodiscitis, vertebral osteomyelitis and bilateral psoas abscesses after acupuncture: diagnosis and treatment with interventional management.
Diverticulum
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Drug-Related Side Effects and Adverse Reactions
Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats.
Drug-Related Side Effects and Adverse Reactions
Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy.
Drug-Related Side Effects and Adverse Reactions
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Dyspnea
Laryngeal Kaposi's Sarcoma Complicated by the Immune Reconstitution Inflammatory Syndrome in an HIV-infected Patient.
Dyspnea
Obstructive jaundice in polycystic liver disease related to coexisting cholangiocarcinoma.
Encephalitis
Phospholipase activities in clinical and environmental isolates of acanthamoeba.
Encephalomyelitis
Increased expression of phospholipase D1 in the spinal cords of rats with experimental autoimmune encephalomyelitis.
Encephalomyelitis
Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Increased expression of phospholipase D1 in the spinal cords of rats with experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.
Endometrial Neoplasms
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
Endometrial Neoplasms
Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.
Endometrial Neoplasms
[A case of recurrent endometrial carcinoma with pleural effusion maintained long SD by pegylated liposomal doxorubicin(PLD)chemotherapy].
Endometriosis
Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis.
Endophthalmitis
Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model.
Enterocolitis, Pseudomembranous
Effects of Clostridium difficile toxin A and toxin B on phospholipase D activation in human promyelocytic leukemic HL60 cells.
Eosinophilia
Platycodin D Attenuates Airway Inflammation in a Mouse Model of Allergic Asthma by Regulation NF-?B Pathway.
Epidural Abscess
Preliminary clinical study: percutaneous lumbar discectomy combined with external drainage for treatment of intervertebral disc infections with epidural abscess.
Epilepsy
A non-mitotic role for aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src.
Epilepsy
Differential expression of phospholipase D isozymes in the hippocampus following kainic acid-induced seizures.
Epilepsy, Temporal Lobe
Differential expression of phospholipase D isozymes in the hippocampus following kainic acid-induced seizures.
Erythema
Case of severe bullous erythema including intertrigo-like eruptions with angioedema induced by pegylated liposomal doxorubicin.
Erythema
Molecular cloning and functional characterization of two isoforms of dermonecrotic toxin from Loxosceles intermedia (brown spider) venom gland.
Exanthema
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Exanthema
Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo.
Exanthema
Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature.
Fallopian Tube Neoplasms
Outcomes with Single Agent LIPO-DOX in Platinum-Resistant Ovarian and Fallopian Tube Cancers and Primary Peritoneal Adenocarcinoma - Chiang Mai University Hospital Experience.
Fatty Liver
Screening for the drug-phospholipid interaction: correlation to phospholipidosis.
Febrile Neutropenia
A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Febrile Neutropenia
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Febrile Neutropenia
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Febrile Neutropenia
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Febrile Neutropenia
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Fetal Alcohol Spectrum Disorders
Functions and pathophysiological roles of phospholipase D in the brain.
Fetal Diseases
Mitogenic effects of phospholipase D and phosphatidic acid in transiently permeabilized astrocytes: effects of ethanol.
Fibrosarcoma
Phospholipase D mediates matrix metalloproteinase-9 secretion in phorbol ester-stimulated human fibrosarcoma cells.
Fibrosarcoma
Release of gelatinase A (matrix metalloproteinase 2) induced by photolysis of caged phosphatidic acid in HT 1080 metastatic fibrosarcoma cells.
Fibrosarcoma
The effects of altered fractionation schedules on the survival of human cell lines differing in their proliferative activity and repair capacity.
Gallstones
Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.
Gangliosidoses, GM2
Requirement of GM2 ganglioside activator for phospholipase D activation.
Gastroenteritis
Molecular and functional evidence of phosphatidylserine synthase in Vibrio parahaemolyticus.
Genetic Diseases, Inborn
Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2.
Genetic Diseases, Inborn
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Glaucoma
Chronic Glaucoma in Dogs: Relationships Between Histologic Lesions and the Gonioscopic Diagnosis of Pectinate Ligament Dysplasia.
Glaucoma
Histopathologic evaluation of the anterior segment of eyes enucleated due to glaucoma secondary to primary lens displacement in 13 canine globes.
Glaucoma
Pectinate ligament dysplasia (PLD) and glaucoma in Flat Coated Retrievers. I. Objectives, technique and results of a PLD survey.
Glaucoma
Pectinate ligament dysplasia and glaucoma in Flat Coated Retrievers. II. Assessment of prevalence and heritability.
Glaucoma
Pectinate ligament dysplasia and narrowing of the iridocorneal angle associated with glaucoma in the English Springer Spaniel.
Glioblastoma
Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP.
Glioblastoma
Induction of the early response protein EGR-1 in human tumour cells after ionizing radiation is correlated with a reduction of repair of lethal lesions and an increase of repair of sublethal lesions.
Glioblastoma
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Glioblastoma
Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma.
Glioblastoma
Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells.
Glioblastoma
Treatment with Gold Nanoparticles Using Cudrania tricuspidata Root Extract Induced Downregulation of MMP-2/-9 and PLD1 and Inhibited the Invasiveness of Human U87 Glioblastoma Cells.
Glioma
(1)H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas.
Glioma
Activation of phospholipase D by platelet-derived growth factor (PDGF) in rat C6 glioma cells: possible role in mitogenic signal transduction.
Glioma
Ca2+ inhibits guanine nucleotide-activated phospholipase D in neural-derived NG108-15 cells.
Glioma
Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models.
Glioma
Different regulation of phospholipase D activity in glioma C6 cells by sphingosine, propranolol, imipramine and phorbol ester.
Glioma
Differential mRNA expression of phospholipase D (PLD) isozymes during cAMP-induced differentiation in C6 glioma cells.
Glioma
Differential roles of Edg-1 and Edg-5, sphingosine 1-phosphate receptors, in the signaling pathways in C6 glioma cells.
Glioma
Effect of ethanol on ATP-induced phospholipases C and D and serine base exchange in glioma C6 cells.
Glioma
Endothelin receptors stimulate both phospholipase C and phospholipase D activities in different cell lines.
Glioma
Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells.
Glioma
Expression and regulation of phospholipase D isoforms in sphingosine and phorbol ester-stimulated glioma C6 cells.
Glioma
Human Phospholipase D Activity Transiently Regulates Pyrimidine Biosynthesis in Malignant Gliomas.
Glioma
Limited metabolic interaction of serine with ethanolamine and choline in the turnover of phosphatidylserine, phosphatidylethanolamine and plasmalogens in cultured glioma cells.
Glioma
Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways.
Glioma
Phorbol myristate acetate-induced Egr-1 expression is suppressed by phospholipase D isozymes in human glioma cells.
Glioma
Phosphatidylethanol biosynthesis in ethanol-exposed NG108-15 neuroblastoma X glioma hybrid cells. Evidence for activation of a phospholipase D phosphatidyl transferase activity by protein kinase C.
Glioma
Phospholipase D hydrolysis of plasmalogen and diacyl ethanolamine phosphoglycerides by protein kinase C dependent and independent mechanisms.
Glioma
Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells.
Glioma
Radiosensitization by inhibition of IkappaB-alpha phosphorylation in human glioma cells.
Glioma
Ro31-8220 inhibits protein kinase C to block the phorbol ester-stimulated release of choline- and ethanolamine-metabolites from C6 glioma cells: p70 S6 kinase and MAPKAP kinase-1beta do not function downstream of PKC in activating PLD.
Glioma
The effect of lonidamine (LND) on radiation and thermal responses of human and rodent cell lines.
Glomerulonephritis, Membranoproliferative
Loss of self-control in the complement system and innate autoreactivity.
Glomerulonephritis, Membranoproliferative
The role of carbohydrate in the structure and function of nephritic factor.
Glomerulonephritis, Membranoproliferative
Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Glomerulonephritis, Membranoproliferative
[Partial lipodystrophy, hypocomplementemia and glomerulonephritis]
Glomerulonephritis, Membranoproliferative
[Production of C3 nephritic factor by cultured lymphocytes derived from glomerulonephritic patients]
Glucose Intolerance
Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota.
Glucose Intolerance
Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice.
Hand-Foot Syndrome
Liposomal anthracycline administration and toxicity management: a nursing perspective.
Hand-Foot Syndrome
Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish.
Hand-Foot Syndrome
Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.
Hand-Foot Syndrome
Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo.
Hand-Foot Syndrome
Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Hand-Foot Syndrome
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review.
Hand-Foot Syndrome
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
Hand-Foot Syndrome
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Hand-Foot Syndrome
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer.
Hand-Foot Syndrome
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Hand-Foot Syndrome
The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Hand-Foot Syndrome
The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD.
Hand-Foot Syndrome
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Hand-Foot Syndrome
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Hand-Foot Syndrome
[Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Hearing Loss
Analysis of the Actual One-Month Usage of Portable Listening Devices in College Students.
Hearing Loss
Effect of Duration of Exposure to Personal Listening Devices on Hearing Thresholds in Young Adults.
Hearing Loss
Reducing the risk of music-induced hearing loss from overuse of portable listening devices: understanding the problems and establishing strategies for improving awareness in adolescents.
Hearing Loss
Use of Personal Listening Devices and Knowledge/Attitude for Greater Hearing Conservation in College Students: Data Analysis and Regression Model Based on 1009 Respondents.
Hearing Loss, Noise-Induced
Cultural and Demographic Factors Influencing Noise Exposure Estimates from Use of Portable Listening Devices in an Urban Environment.
Hearing Loss, Noise-Induced
Early Indication of Noise-Induced Hearing Loss in Young Adult Users of Personal Listening Devices.
Hearing Loss, Noise-Induced
Objective Measurement of Listening Device Use and Its Relation to Hearing Acuity.
Heart Arrest
Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women.
Heart Arrest
Revised Cardiac Risk Index as a Predictor for Myocardial Infarction and Cardiac Arrest Following Posterior Lumbar Decompression.
Heart Defects, Congenital
Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathy.
Heart Diseases
N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of phospholipase D as a possible mechanism.
Heart Diseases
The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials.
Heart Failure
Alterations of sarcolemmal phospholipase D and phosphatidate phosphohydrolase in congestive heart failure.
Heart Failure
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Heart Failure
Early experience with the Occlutech PLD occluder for mitral paravalvar leak closure through a hybrid transapical approach.
Heart Failure
Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction.
Heart Failure
High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies.
Heart Failure
N-methylethanolamine attenuates cardiac fibrosis and improves diastolic function: inhibition of phospholipase D as a possible mechanism.
Hemangiosarcoma
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
Hemangiosarcoma
Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.
Hemangiosarcoma
Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma.
Hematuria
Developing recombinant phospholipase D1 (rPLD1) toxoid from Iranian Hemiscorpius lepturus scorpion and its protective effects in BALB/c mice.
Hematuria
Obstructive jaundice in a patient with polycystic liver disease complicated with polycystic kidney and polycystic lung: A case report.
Hepatitis C
Phospholipase D activity is elevated in hepatitis C virus core protein-transformed NIH3T3 mouse fibroblast cells.
Hepatomegaly
Extended Liver Resection for Polycystic Liver Disease Can Challenge Liver Transplantation.
Hepatomegaly
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Hepatomegaly
Modified technique of total hepatectomy in polycystic liver disease with caval flow preservation: the exposure left lateral sectionectomy.
Hepatomegaly
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.
Hepatomegaly
Preserving the organ donor pool and suprahepatic vena cava: Case series of transverse hepatectomy for polycystic liver disease.
Hepatomegaly
[Orthotopic liver transplantation in therapy of advanced polycystic liver disease]
Hereditary Complement Deficiency Diseases
Partial lipodystrophy, meningococcal meningitis and nephritis.
Herpes Zoster
A role for phospholipase D in angiotensin II-induced protein kinase D activation in adrenal glomerulosa cell models.
Herpes Zoster
Phospholipase D activity underlies very-low-density lipoprotein (VLDL)-induced aldosterone production in adrenal glomerulosa cells.
Herpes Zoster
Sphingosine-1-phosphate stimulates aldosterone secretion through a mechanism involving the PI3K/PKB and MEK/ERK 1/2 pathways.
Hodgkin Disease
Proteinaceous Lymphadenopathy in a Young Patient With History of Classical Hodgkin Lymphoma: A Case Report With Literature Review.
Hyperglycemia
Possible involvement of phospholipase D and protein kinase C in vascular growth induced by elevated glucose concentration.
Hyperpigmentation
Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo.
Hypersensitivity
Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.
Hypersensitivity
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
Hypersensitivity
Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Hypersensitivity
Defective recovery from potentially lethal damage in some human fibroblast cell strains.
Hypersensitivity
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Hypersensitivity
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
Hypersensitivity
Hypersensitivity reaction to pegylated liposomal doxorubicin administration for Mullerian carcinoma in Japanese women.
Hypersensitivity
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Hypersensitivity
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Hypersensitivity
Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
Hypersensitivity
The TRPM8 channel forms a complex with the 5-HT(1B) receptor and phospholipase D that amplifies its reversal of pain hypersensitivity.
Hypersensitivity
[Study on eosinophil cationic protein (ECP) and arylsulfatase B in nasal secretions and sera from patients with nasal allergy]
Hypertension
Angiotensins differentially activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats.
Hypertension
AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity.
Hypertension
Severe polycystic liver diseases: hepatectomy or waiting for liver transplantation?: Two case reports.
Hypertension
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Hypertension
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
Hypertension, Malignant
ANG II stimulates phospholipase D through PKCzeta activation in VSMC: implications in adhesion, spreading, and hypertrophy.
Hypotension
Phospholipase D2 loss results in increased blood pressure via inhibition of the endothelial nitric oxide synthase pathway.
Hypotension
Postoperative liver dysfunction after total arch replacement combined with frozen elephant trunk implantation: incidence, risk factors and outcomes.
Hypothyroidism
Impairment of the sarcolemmal phospholipase D-phosphatidate phosphohydrolase pathway in diabetic cardiomyopathy.
Infarction, Middle Cerebral Artery
Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol.
Infections
A novel approach for an immunogen against Corynebacterium pseudotuberculosis infection: An Escherichia coli bacterin expressing phospholipase D.
Infections
A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Infections
Activation of host phospholipases C and D in macrophages after infection with Listeria monocytogenes.
Infections
Arabidopsis phospholipase D?1 modulates defense responses to bacterial and fungal pathogens.
Infections
Aspergillus fumigatus phospholipase D may enhance reactive oxygen species production by accumulation of histone deacetylase 6.
Infections
Bordetella Dermonecrotic Toxin Is a Neurotropic Virulence Factor That Uses CaV3.1 as the Cell Surface Receptor.
Infections
CCR5 signaling through phospholipase D involves p44/42 MAP-kinases and promotes HIV-1 LTR-directed gene expression.
Infections
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins.
Infections
Cloning and expression of the phospholipase D gene from Corynebacterium pseudotuberculosis in Escherichia coli.
Infections
Comparison of an interferon-gamma to a phospholipase D enzyme-linked immunosorbent assay for diagnosis of Corynebacterium pseudotuberculosis infection in experimentally infected goats.
Infections
Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers.
Infections
Disc space infection and vertebral osteomyelitis as a complication of percutaneous lateral discectomy.
Infections
Effect of the purinergic receptor P2X7 on Chlamydia infection in cervical epithelial cells and vaginally infected mice.
Infections
Efficacy and safety of selective decontamination of the digestive tract (SDD) to prevent recurrent hepatic cyst infections in polycystic liver disease: a retrospective case series.
Infections
Expression analysis of a plum pathogenesis related 10 (PR10) protein during brown rot infection.
Infections
Expression of phospholipase D, the major virulence factor of Corynebacterium pseudotuberculosis, is regulated by multiple environmental factors and plays a role in macrophage death.
Infections
Expression of the dermonecrotic toxin by Bordetella bronchiseptica is not necessary for predisposing to infection with toxigenic Pasteurella multocida.
Infections
Genetic and biochemical analyses of a eukaryotic-like phospholipase D of Pseudomonas aeruginosa suggest horizontal acquisition and a role for persistence in a chronic pulmonary infection model.
Infections
Geographic information system-based analysis of COVID-19 cases in India during pre-lockdown, lockdown, and unlock phases.
Infections
Gonococcal phospholipase d modulates the expression and function of complement receptor 3 in primary cervical epithelial cells.
Infections
Identification of adsorption inhibition, restriction/modification and abortive infection type phage resistance systems in Lactococcus lactis strains.
Infections
In vivo synthesis of monolysocardiolipin and cardiolipin by Acinetobacter baumannii phospholipase D and effect on cationic antimicrobial peptide resistance.
Infections
Influence of Corynebacterium pseudotuberculosis infection on level of acute phase proteins in goats.
Infections
Inhibition of chlamydial infectious activity due to P2X7R-dependent phospholipase D activation.
Infections
Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells.
Infections
Long-circulating liposomal daptomycin enhances protection against systemic methicillin-resistant Staphylococcus aureus infection with improved therapeutic potential.
Infections
Neisseria gonorrhoeae PLD directly interacts with Akt kinase upon infection of primary, human, cervical epithelial cells.
Infections
One-stage closure of large bronchopleural fistula with pedicled latissimus dorsi muscle flap after preemptive antibiotics: A case report.
Infections
Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.
Infections
Phospholipase D and the Mitogen Phosphatidic Acid in Human Disease: Inhibitors of PLD at the Crossroads of Phospholipid Biology and Cancer.
Infections
Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibition.
Infections
Phospholipase D-mediated activation of IQGAP1 through Rac1 regulates hyperoxia-induced p47phox translocation and reactive oxygen species generation in lung endothelial cells.
Infections
Phospholipase D-neutralization in serodiagnosis of Arcanobacterium haemolyticum and Corynebacterium pseudotuberculosis infections.
Infections
Phospholipase gene expression during Paracoccidioides brasiliensis morphological transition and infection.
Infections
Preliminary clinical study: percutaneous lumbar discectomy combined with external drainage for treatment of intervertebral disc infections with epidural abscess.
Infections
Requirement for either a host- or pectin-induced pectate lyase for infection of Pisum sativum by Nectria hematococca.
Infections
Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model.
Infections
Small protein A and phospholipase D immunization serves a protective role in a mouse pneumonia model of Acinetobacter baumannii infection.
Infections
Sodium butyrate ameliorates Corynebacterium pseudotuberculosis infection in RAW264.7 macrophages and C57BL/6 mice.
Infections
Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.
Infections
The role of a phospholipase (PLD) in virulence of Purpureocillium lilacinum (Paecilomyces lilacinum).
Infections
Transcription, expression, localization and immunoreactivity of Chlamydophila pneumoniae Phospholipase D protein.
Infections
Vaccination confers significant protection of sheep against infection with a virulent United Kingdom strain of Corynebacterium pseudotuberculosis.
Infections
[Listeria-induced host cellular actin cytoskeleton rearrangement and phospholipase D]
Infertility
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: Production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
Inflammatory Bowel Diseases
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.
Influenza, Human
Discovery of a highly selective PLD2 inhibitor (ML395): a new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strains.
Influenza, Human
Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibition.
Insulin Resistance
Adenoviral gene transfer of PLD1-D4 enhances insulin sensitivity in mice by disrupting phospholipase D1 interaction with PED/PEA-15.
Insulin Resistance
C2C12 skeletal muscle cells exposure to phosphatidylcholine triggers IGF-1 like-responses.
Insulin Resistance
Discovery of Small Peptide Antagonists of PED/PEA15-D4? Interaction from Simplified Combinatorial Libraries.
Insulin Resistance
Functional characterisation of ADP ribosylation factor-like protein 15 in rheumatoid arthritis synovial fibroblasts.
Insulin Resistance
Modulation of Insulin Sensitivity of Hepatocytes by the Pharmacological Downregulation of Phospholipase D.
Insulin Resistance
On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities.
Insulin Resistance
Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice.
Insulin Resistance
Targeting of PED/PEA-15 molecular interaction with phospholipase D1 enhances insulin sensitivity in skeletal muscle cells.
Intervertebral Disc Displacement
Feasibility of Percutaneous Lumbar Discectomy Combined with Percutaneous Cementoplasty for Symptomatic Lumbar Disc Herniation with Modic Type I Endplate Changes.
Intervertebral Disc Displacement
Long-Term Outcomes of Patients with Lumbar Disc Herniation Treated with Percutaneous Discectomy: Comparative Study with Microendoscopic Discectomy.
Intervertebral Disc Displacement
[Long-term outcomes of percutaneous lumbar discectomy and microendoscopic discectomy for lumbar disc herniation]
Intervertebral Disc Displacement
[The clinical effects of percutaneous lumbar discectomy combined with sodium hyaluronate in the treatment of lumbar intervertebral disc herniation]
Ischemic Stroke
Pharmacological inhibition of phospholipase d protects mice from occlusive thrombus formation and ischemic stroke--brief report.
Ischemic Stroke
The role of glycoprotein Ibalpha and von Willebrand factor interaction in stroke development.
Kidney Diseases
Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation.
Kidney Failure, Chronic
Extended Liver Resection for Polycystic Liver Disease Can Challenge Liver Transplantation.
Kidney Failure, Chronic
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
Kidney Neoplasms
HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Kidney Neoplasms
Increased activity and intranuclear expression of phospholipase D2 in human renal cancer.
Kidney Neoplasms
Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.
Leiomyoma
Contribution of phospholipase D in endothelin-1-mediated extracellular signal-regulated kinase activation and proliferation in rat uterine leiomyoma cells.
Leiomyoma
Role of lysophosphatidic acid in the regulation of uterine leiomyoma cell proliferation by phospholipase D and autotaxin.
Leishmaniasis
Shedding light on lipid metabolism in Kinetoplastida: A phylogenetic analysis of phospholipase D protein homologs.
Leukemia
Activation of membrane-bound phospholipase D by protein kinase C in HL60 cells: synergistic action of a small GTP-binding protein RhoA.
Leukemia
Antigen-mediated phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells: possible involvement of calcium/calmodulin.
Leukemia
Brefeldin A inhibits antigen- or calcium ionophore-mediated but not PMA-induced phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Ceramide inhibits IgE-mediated activation of phospholipase D, but not of phospholipase C, in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Effect of Clostridium difficile toxin B on IgE receptor-mediated signal transduction in rat basophilic leukemia cells: inhibition of phospholipase D activation.
Leukemia
Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation.
Leukemia
Hexadecylphosphocholine does not influence phospholipase D and sphingomyelinase activity in human leukemia cells.
Leukemia
Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
Leukemia
Involvement of tyrosine phosphorylation in IgE receptor-mediated phospholipase D activation in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells.
Leukemia
Phenylarsine oxide (PAO)-mediated activation of phospholipase D in rat basophilic leukemia (RBL-2H3) cells: possible involvement of calcium and protein kinase C.
Leukemia
Phospholipase D (PLD) gene expression in human neutrophils and HL-60 differentiation.
Leukemia
Pleiotropic role of Rac in mast cell activation revealed by a cell permeable Bordetella dermonecrotic fusion toxin.
Leukemia
Potent activation of phospholipase D by phenylarsine oxide in rat basophilic leukemia (RBL-2H3) cells.
Leukemia
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Leukemia
The pro-apoptotic drug camptothecin stimulates phospholipase D activity and diacylglycerol production in the nucleus of HL-60 human promyelocytic leukemia cells.
Leukemia
[Effects of antiallergic drug, pemirolast potassium on phospholipase D activation in antigen-stimulated rat basophilic leukemia (RBL-2H3) cells]
Leukemia
[The involvement of protein kinase C isozymes in activation of phospholipase D and secretion of serotonin in rat basophilic leukemia cells]
Leukemia, B-Cell
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Leukemia, Erythroblastic, Acute
Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells.
Leukemia, Erythroblastic, Acute
Direct relationship between intracellular calcium mobilization and phospholipase D activation in prostaglandin E-stimulated human erythroleukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effect of glycosylphosphatidylinositol specific phospholipase D gene expression levels on complement mediated killing of leukemic cells in patients with chronic myeloid leukemia.
Leukemia, Myeloid
[Effect of GPI-PLD on adhesion function of bone marrow mononuclear cell from patients with myeloid leukemia and its mechanism]
Leukemia, Myeloid, Acute
Expression and clinical significance of phospholipase D1 in de novo acute myeloid leukemia.
Leukemia, Myeloid, Acute
[Expression and activity of glycosylphosphatidilinoditol-specific phospholipase d mRNA in bone marrow mononuclear cells isolated from patient with acute myeloid leukemia and their significance]
Leukomalacia, Periventricular
[Procedural learning disorder: neuropsychological characteristics.]
Leukoplakia, Oral
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.
Liver Cirrhosis
A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Liver Cirrhosis
The Role of Phospholipase D1 in Liver Fibrosis Induced by Dimethylnitrosamine In Vivo.
Liver Diseases
A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Liver Diseases
Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation.
Liver Diseases
Extended Liver Resection for Polycystic Liver Disease Can Challenge Liver Transplantation.
Liver Diseases
Ganab Haploinsufficiency Does Not Cause Polycystic Kidney Disease or Polycystic Liver Disease in Mice.
Liver Diseases
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
Liver Diseases
Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study.
Liver Diseases
Pancreatic ductal adenocarcinoma associated with Potter type III cystic disease.
Liver Diseases
Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.
Liver Diseases
Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect.
Liver Diseases
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.
Liver Diseases
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
Liver Diseases
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Liver Diseases
Postoperative liver dysfunction after total arch replacement combined with frozen elephant trunk implantation: incidence, risk factors and outcomes.
Liver Diseases
Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values.
Liver Diseases
Preoperative Phenacetin Metabolism Test in the Prediction of Postoperative Liver Dysfunction of Patients with Hepatocellular Carcinoma.
Liver Diseases
Preserving the organ donor pool and suprahepatic vena cava: Case series of transverse hepatectomy for polycystic liver disease.
Liver Diseases
Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
Liver Diseases
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
Liver Diseases
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Liver Failure
Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
Liver Failure
Fulminant liver failure in a patient affected by polycystic liver disease and liver metastases from breast carcinoma.
Liver Failure
Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.
Liver Failure, Acute
Fulminant liver failure in a patient affected by polycystic liver disease and liver metastases from breast carcinoma.
Liver Neoplasms
Kinetic study of prolidase activity in erythrocytes against different substrates using capillary electrophoresis with electrochemiluminescence detection.
Lung Diseases
Persistent and chronic lung disease in HIV-1 infected and uninfected African children.
Lung Diseases
Phospholipase D signaling mediates reactive oxygen species-induced lung endothelial barrier dysfunction.
Lung Diseases, Interstitial
Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer.
Lung Diseases, Interstitial
Pulmonary Fibrosis after Pegylated Liposomal Doxorubicin in Elderly Patient with Cutaneous Angiosarcoma.
Lung Diseases, Interstitial
[Risk factors for pleural lung disease in children with juvenile idiopathic arthritis].
Lung Injury
Hyperoxia alters phorbol ester-induced phospholipase D activation in bovine lung microvascular endothelial cells.
Lung Neoplasms
A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer.
Lung Neoplasms
Association between previous lung diseases and lung cancer risk: a systematic review and meta-analysis.
Lung Neoplasms
D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
Lung Neoplasms
Down-regulation of Phospholipase D Stimulates Death of Lung Cancer Cells Involving Up-regulation of the Long ncRNA ANRIL.
Lung Neoplasms
Inhibition of potential lethal damage repair and related gene expression after carbon-ion beam irradiation to human lung cancer grown in nude mice.
Lung Neoplasms
Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer.
Lung Neoplasms
Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Lupus Erythematosus, Systemic
Identification and functional analysis of a novel phospholipase D2 gene mutation associated with familial systemic lupus erythematosus.
Lymphadenitis
Assessment of blood changes post-challenge with Corynebacterium pseudotuberculosis and its exotoxin (phospholipase D): A comprehensive study in goat.
Lymphadenitis
Caseous lymphadenitis vaccine development: site-specific inactivation of the Corynebacterium pseudotuberculosis phospholipase D gene.
Lymphadenitis
Distribution of PLD and FagA, B, C and D genes in Corynebacterium pseudotuberculosis isolates from sheep and goats with caseus lymphadenitis.
Lymphadenitis
Efficacy of an ovine caseous lymphadenitis vaccine formulated using a genetically inactive form of the Corynebacterium pseudotuberculosis phospholipase D.
Lymphadenitis
Outbreak with clonally related isolates of Corynebacterium ulcerans in a group of water rats.
Lymphadenitis
Protection of sheep against caseous lymphadenitis by use of a single oral dose of live recombinant Corynebacterium pseudotuberculosis.
Lymphadenitis
Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep.
Lymphadenopathy
Lymph node biopsies in HIV-infected and non-infected children with persistent lung disease.
Lymphatic Metastasis
Immunoexpression of VEGFR-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.
Lymphatic Metastasis
Participation of hypoxia-inducible factor-1? and lymphangiogenesis in metastatic and non-metastatic lower lip squamous cell carcinoma.
Lymphoma
Changes of phospholipase D activity in TNF-alpha and anti-Fas/Apo1 monoclonal antibody induced apoptosis in HL-60 and A20 cells.
Lymphoma
Differential effects of Fas cross-linking on phospholipase D activation and related lipid metabolism in Fas-resistant A20 cells.
Lymphoma
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells.
Lymphoma
Fas-mediated activation of phospholipase D is coupled to the stimulation of phosphatidylcholine-specific phospholipase C in A20 cells.
Lymphoma
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Lymphoma
Novel endogenous negative modulators of platelet function as potential anti-thrombotic targets.
Lymphoma
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
Lymphoma
Phospholipase D2 Enhances Epidermal Growth Factor-Induced Akt Activation in EL4 Lymphoma Cells.
Lymphoma
Proteinaceous Lymphadenopathy in a Young Patient With History of Classical Hodgkin Lymphoma: A Case Report With Literature Review.
Lymphoma
Wortmannin, an inhibitor of phospholipase D activation, selectively blocks major histocompatibility complex class II-restricted antigen presentation.
Lymphoma, B-Cell
Changes of phospholipase D activity in TNF-alpha and anti-Fas/Apo1 monoclonal antibody induced apoptosis in HL-60 and A20 cells.
Lymphoma, B-Cell
Fas-mediated activation of phospholipase D is coupled to the stimulation of phosphatidylcholine-specific phospholipase C in A20 cells.
Lymphoma, B-Cell
[Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Lymphoma, Large B-Cell, Diffuse
[Clinical Efficiency and Safety of the First-line CHOP Regimen Containing PLD Applied to Treat Aged Patients with Advanced DLBCL].
Lymphoma, Non-Hodgkin
Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin - Consensus of the lymphoma group of the Working Group Dermatologic Oncology.
Lymphoma, T-Cell, Cutaneous
Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
Lymphoma, T-Cell, Cutaneous
Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients.
Lymphoma, T-Cell, Peripheral
Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas.
Mastitis
Platycodin D suppressed LPS-induced inflammatory response by activating LXR? in LPS-stimulated primary bovine mammary epithelial cells.
Median Neuropathy
Acute Median Neuropathy and Carpal Tunnel Release in Perilunate Injuries Can We Predict Who Gets a Median Neuropathy?
Medulloblastoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Melanoma
A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma.
Melanoma
Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma.
Melanoma
Down-regulation of melanogenesis by phospholipase D2 through ubiquitin proteasome-mediated degradation of tyrosinase.
Melanoma
Enhancement of radiosensitivity of cultured mammalian cells by neocarzinostatin. II. Fixation of potentially lethal damage.
Melanoma
Expression and regulation of phospholipase D isoenzymes in human melanoma cells and primary melanocytes.
Melanoma
Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.
Melanoma
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.
Melanoma
PKCdelta inhibits PKCalpha-mediated activation of phospholipase D1 in a manner independent of its protein kinase activity.
Melanoma
Protein kinase C alpha associates with phospholipase D1 and enhances basal phospholipase D activity in a protein phosphorylation-independent manner in human melanoma cells.
Melanoma
Radiosensitizing effects of misonidazole and SR 2508 on a human melanoma transplanted in nude mice: influence on repair of potentially lethal damage.
Melanoma
Response of cells of human origin, normal and malignant, to acute and low dose rate irradiation.
Melanoma, Experimental
Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma.
Melanoma, Experimental
Involvement of phospholipase D1 in melanogenesis of mouse B16 melanoma cells.
Melanoma, Experimental
Negative regulation of melanogenesis by phospholipase D1 through mTOR/p70 S6 kinase 1 signaling in mouse B16 melanoma cells.
Memory Disorders
Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits.
Metabolic Syndrome
Phospholipase D As a Potential Modulator of Metabolic Syndrome: Impact of Functional Foods.
Motor Neuron Disease
Using Drosophila melanogaster To Discover Human Disease Genes: An Educational Primer for Use with "Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target".
Mouth Neoplasms
[The experiment of pegylated liposomal doxorubicin to therapy tongue cancer and metastases lymph nodes]
Mucositis
Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish.
Mucositis
Oral squamous cell carcinoma in a patient treated with long-term pegylated liposomal doxorubicin for recurrent ovarian cancer.
Mucositis
Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer.
Mucositis
Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Mucositis
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
Mucositis
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Mucositis
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Mucositis
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Mucositis
Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Mucositis
Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Mucositis
The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials.
Mucositis
Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Multiple Myeloma
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Multiple Myeloma
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Multiple Myeloma
Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety.
Multiple Myeloma
Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma.
Multiple Myeloma
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Multiple Sclerosis, Relapsing-Remitting
Phospholipase D1 expression analysis in relapsing-remitting multiple sclerosis patients.
Muscle Cramp
Sodium butyrate ameliorates Corynebacterium pseudotuberculosis infection in RAW264.7 macrophages and C57BL/6 mice.
Muscular Dystrophies
Characterization of C-protein isoforms expressed in developing, denervated, and dystrophic chicken skeletal muscles by two-dimensional gel electrophoresis.
Mycoses
The OXI1 kinase pathway mediates Piriformospora indica-induced growth promotion in Arabidopsis.
Myocardial Infarction
Enzymatic Activity Is Not Required for Phospholipase D Mediated TNF-? Regulation and Myocardial Healing.
Myocardial Infarction
Expression of phospholipase D isozymes in scar and viable tissue in congestive heart failure due to myocardial infarction.
Myocardial Ischemia
Enzymatic Activity Is Not Required for Phospholipase D Mediated TNF-? Regulation and Myocardial Healing.
Myocardial Ischemia
Pivotal role of phospholipase D1 in tumor necrosis factor-?-mediated inflammation and scar formation after myocardial ischemia and reperfusion in mice.
Myocarditis
Increased expression of phospholipase D in the heart with experimental autoimmune myocarditis in Lewis rats.
Neoplasm Metastasis
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis.
Neoplasm Metastasis
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports.
Neoplasm Metastasis
Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model.
Neoplasm Metastasis
Correlation between lymphatic vessel density and regional metastasis in squamous cell carcinoma of the tongue.
Neoplasm Metastasis
Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma.
Neoplasm Metastasis
Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
Neoplasm Metastasis
Differential Expression of Ccn4 and Other Genes Between Metastatic and Non-metastatic EL4 Mouse Lymphoma Cells.
Neoplasm Metastasis
Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in EL4 lymphoma cells.
Neoplasm Metastasis
Fulminant liver failure in a patient affected by polycystic liver disease and liver metastases from breast carcinoma.
Neoplasm Metastasis
How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD.
Neoplasm Metastasis
Immunoexpression of VEGFR-3, but not the immunoexpression of VEGF-C or lymphatic density, is correlated with metastasis in lower lip squamous cell carcinoma.
Neoplasm Metastasis
Increased phospholipase D activity contributes to tumorigenesis in prostate cancer cell models.
Neoplasm Metastasis
Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis.
Neoplasm Metastasis
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells.
Neoplasm Metastasis
MicroRNA miR-145-5p inhibits Phospholipase D 5 (PLD5) to downregulate cell proliferation and metastasis to mitigate prostate cancer.
Neoplasm Metastasis
Participation of hypoxia-inducible factor-1? and lymphangiogenesis in metastatic and non-metastatic lower lip squamous cell carcinoma.
Neoplasm Metastasis
Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: a case report.
Neoplasm Metastasis
Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model.
Neoplasm Metastasis
Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.
Neoplasm Metastasis
PLD-Specific Small-Molecule Inhibitors Decrease Tumor-Associated Macrophages and Neutrophils Infiltration in Breast Tumors and Lung and Liver Metastases.
Neoplasm Metastasis
Proliferative and metastatic roles for Phospholipase D in mouse models of cancer.
Neoplasm Metastasis
Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2.
Neoplasm Metastasis
Release of gelatinase A (matrix metalloproteinase 2) induced by photolysis of caged phosphatidic acid in HT 1080 metastatic fibrosarcoma cells.
Neoplasm Metastasis
SCD1 activity promotes cell migration via a PLD-mTOR pathway in the MDA-MB-231 triple-negative breast cancer cell line.
Neoplasm Metastasis
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Neoplasm Metastasis
Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Neoplasm Metastasis
Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.
Neoplasm Metastasis
Two sites of action for PLD2 inhibitors: The enzyme catalytic center and an allosteric, phosphoinositide biding pocket.
Neoplasm Metastasis
[Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Neoplasms
1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for Phospholipase D.
Neoplasms
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis.
Neoplasms
A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation.
Neoplasms
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Neoplasms
A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
Neoplasms
A feedback mechanism between PLD and deadenylase PARN for the shortening of eukaryotic poly(A) mRNA tails that is deregulated in cancer cells.
Neoplasms
A NEW SIGNALING PATHWAY (JAK-FES-PLD) THAT IS ENHANCED IN HIGHLY PROLIFERATIVE BREAST CANCER CELLS.
Neoplasms
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Neoplasms
A phospholipase D and protein kinase C inhibitor blocks the spreading of murine mammary adenocarcinoma cells altering f-actin and beta1-integrin point contact distribution.
Neoplasms
A Repertoire of MicroRNAs Regulates Cancer Cell Starvation by Targeting Phospholipase D in a Feedback Loop That Operates Maximally in Cancer Cells.
Neoplasms
A Smart "Sense-and-Treat" Nanoplatform Based on Semiconducting Polymer Nanoparticles for Precise Photothermal-Photodynamic Combined Therapy.
Neoplasms
Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
Neoplasms
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Neoplasms
Antagonistic effects of protein kinase C alpha and delta on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor.
Neoplasms
Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.
Neoplasms
Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model.
Neoplasms
Application of carbonic anhydrase inhibitors to increase the penetration of doxorubicin and its liposomal formulation into 2D and 3D triple negative breast cancer cell cultures.
Neoplasms
Asiatic acid enhances intratumor delivery and the antitumor effect of pegylated liposomal doxorubicin by reducing tumor-stroma collagen.
Neoplasms
Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer.
Neoplasms
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Neoplasms
Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Neoplasms
Caspase cleavage of phospholipase D1 in vitro alters its regulation and reveals a novel property of the "loop" region.
Neoplasms
Cell Invasion of Highly Metastatic MTLn3 Cancer Cells Is Dependent on Phospholipase D2 (PLD2) and Janus Kinase 3 (JAK3).
Neoplasms
Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells.
Neoplasms
Changes of phospholipase D activity in TNF-alpha and anti-Fas/Apo1 monoclonal antibody induced apoptosis in HL-60 and A20 cells.
Neoplasms
Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.
Neoplasms
Clinical Risk Factors of PEGylated Liposomal Doxorubicin Induced Palmar Plantar Erythrodysesthesia in Recurrent Ovarian Cancer Patients.
Neoplasms
Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer.
Neoplasms
Coenzyme Q10 attenuates rat hepatocarcinogenesis via the reduction of CD59 expression and phospholipase D activity.
Neoplasms
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
Neoplasms
Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets.
Neoplasms
Contribution of phospholipase D in endothelin-1-mediated extracellular signal-regulated kinase activation and proliferation in rat uterine leiomyoma cells.
Neoplasms
Crystal structure of human PLD1 provides insight into activation by PI(4,5)P2 and RhoA.
Neoplasms
Design and evaluation of a phospholipase D based drug delivery strategy of novel phosphatidyl-prodrug.
Neoplasms
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Neoplasms
Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
Neoplasms
Detection of X-ray damage repair by the immediate versus delayed plating technique is dependent on cell shape and cell concentration.
Neoplasms
Direct and Continuous Measurement of Phospholipase D Activities Using the Chelation-Enhanced Fluorescence Property of 8-Hydroxyquinoline.
Neoplasms
Discrepancies between patterns of potentially lethal damage repair in the RIF-1 tumor system in vitro and in vivo.
Neoplasms
Diverging signal transduction pathways activated by interleukin-8 and related chemokines in human neutrophils: interleukin-8, but not NAP-2 or GRO alpha, stimulates phospholipase D activity.
Neoplasms
Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Neoplasms
Down-regulation of MicroRNAs (MiRs) 203, 887, 3619 and 182 Prevents Vimentin-triggered, Phospholipase D (PLD)-mediated Cancer Cell Invasion.
Neoplasms
Down-regulation of Phospholipase D Stimulates Death of Lung Cancer Cells Involving Up-regulation of the Long ncRNA ANRIL.
Neoplasms
Down-regulation of phospholipase D2 mRNA in neonatal rat brainstem and cerebellum after hypoxia-ischemia.
Neoplasms
Doxorubicin liposomes cell penetration enhancement and its potential drawbacks for the tumor targeting efficiency.
Neoplasms
Effect of priming on activation and localization of phospholipase D-1 in human neutrophils.
Neoplasms
Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
Neoplasms
Effects of inhibitors of radiation-induced potentially lethal damage repair on chemotherapy in murine tumors.
Neoplasms
Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models.
Neoplasms
Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Neoplasms
Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Neoplasms
Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
Neoplasms
Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers.
Neoplasms
Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Neoplasms
Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
Neoplasms
Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Neoplasms
Enzymatic Activity Is Not Required for Phospholipase D Mediated TNF-? Regulation and Myocardial Healing.
Neoplasms
Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
Neoplasms
Evidence for protein kinase C independent activation of phospholipase D by phorbol esters in lymphocytes.
Neoplasms
Evidence for the expression of radiation-induced potentially lethal damage being a p53-dependent process.
Neoplasms
Expression and clinical significance of phospholipase D1 in de novo acute myeloid leukemia.
Neoplasms
Expression and Function of the Endocannabinoid Modulating Enzymes Fatty Acid Amide Hydrolase and N-Acylphosphatidylethanolamine-Specific Phospholipase D in Endometrial Carcinoma.
Neoplasms
Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Neoplasms
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
Neoplasms
Fine mapping of the uterine leiomyoma locus on 1q43 close to a lncRNA in the RGS7-FH interval.
Neoplasms
Functional role of phospholipase D (PLD) in di(2-ethylhexyl) phthalate-induced hepatotoxicity in Sprague-Dawley rats.
Neoplasms
G0 cell cycle arrest alone is insufficient for enabling the repair of ionizing radiation-induced potentially lethal damage.
Neoplasms
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
Neoplasms
Gonadotropin-releasing hormone signaling pathways in an experimental ovarian tumor.
Neoplasms
Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage.
Neoplasms
HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Neoplasms
High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies.
Neoplasms
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.
Neoplasms
How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD.
Neoplasms
HPV-16 E7 expression up-regulates phospholipase D activity and promotes rapamycin resistance in a pRB-dependent manner.
Neoplasms
Human Phospholipase D Activity Transiently Regulates Pyrimidine Biosynthesis in Malignant Gliomas.
Neoplasms
Hypoxia-inducible factor 1-alpha up-regulates the expression of phospholipase D2 in colon cancer cells under hypoxic conditions.
Neoplasms
Identification of genes associated with histologic tumor grade of esophageal squamous cell carcinoma.
Neoplasms
Importance of cell proliferative state and potentially lethal damage repair on radiation effectiveness: implications for combined tumor treatments (review).
Neoplasms
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Neoplasms
Improving antitumor efficacy of PEGylated liposomal doxorubicin by dual targeting of tumor cells and tumor endothelial cells using anti-p32 CGKRK peptide.
Neoplasms
In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site.
Neoplasms
In-depth proteome analysis of the rubber particle of Hevea brasiliensis (para rubber tree).
Neoplasms
Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin.
Neoplasms
Increased activity and expression of phospholipase D2 in human colorectal cancer.
Neoplasms
Increased phospholipase D activity contributes to tumorigenesis in prostate cancer cell models.
Neoplasms
Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D.
Neoplasms
Inhibition of phospholipase D blocks activation of fibrinogen-adherent neutrophils by tumor necrosis factor.
Neoplasms
Inhibition of potential lethal damage repair and related gene expression after carbon-ion beam irradiation to human lung cancer grown in nude mice.
Neoplasms
Inhibition of recovery from potentially lethal damage by chemicals in Chinese hamster V79 A cells.
Neoplasms
Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.
Neoplasms
Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors.
Neoplasms
Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors.
Neoplasms
Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22.
Neoplasms
Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis.
Neoplasms
Kinetic study of prolidase activity in erythrocytes against different substrates using capillary electrophoresis with electrochemiluminescence detection.
Neoplasms
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells.
Neoplasms
Leptin increases TNF-? expression and production through phospholipase D1 in Raw 264.7 cells.
Neoplasms
Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin in vivo.
Neoplasms
Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Neoplasms
LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.
Neoplasms
Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods.
Neoplasms
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
Neoplasms
Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies.
Neoplasms
Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
Neoplasms
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
Neoplasms
Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
Neoplasms
mRNA profile provides novel insights into stress adaptation in mud crab megalopa, Scylla paramamosain after salinity stress.
Neoplasms
mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells.
Neoplasms
Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D.
Neoplasms
Mutation of Y179 on phospholipase D2 (PLD2) upregulates DNA synthesis in a PI3K-and Akt-dependent manner.
Neoplasms
Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
Neoplasms
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Neoplasms
Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts.
Neoplasms
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Neoplasms
Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer.
Neoplasms
Oesophageal causes of dysphagia localised only to the pharynx: Implications for the suspected head and neck cancer pathway.
Neoplasms
Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas.
Neoplasms
Oral Squamous Cell Carcinoma as a Complication of Treatment for Recurrent High-Grade Serous Cancer.
Neoplasms
Outcomes with Single Agent LIPO-DOX in Platinum-Resistant Ovarian and Fallopian Tube Cancers and Primary Peritoneal Adenocarcinoma - Chiang Mai University Hospital Experience.
Neoplasms
Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-kappaB/Sp1-mediated signaling pathways.
Neoplasms
Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells.
Neoplasms
Participation of hypoxia-inducible factor-1? and lymphangiogenesis in metastatic and non-metastatic lower lip squamous cell carcinoma.
Neoplasms
Paxillin phosphorylation and complexing with Erk and FAK are regulated by PLD activity in MDA-MB-231 cells.
Neoplasms
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
Neoplasms
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
Neoplasms
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
Neoplasms
Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study.
Neoplasms
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Neoplasms
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
Neoplasms
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Neoplasms
Perfusion imaging of neuroblastoma and nephroblastoma in a paediatric population using pseudo-continuous arterial spin-labelling magnetic resonance imaging.
Neoplasms
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.
Neoplasms
Pharmacokinetics of the intraperitoneal nanoparticle pegylated liposomal doxorubicin in patients with peritoneal metastases.
Neoplasms
Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy.
Neoplasms
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Neoplasms
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.
Neoplasms
Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy.
Neoplasms
Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Neoplasms
Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract.
Neoplasms
Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells.
Neoplasms
Phorbol myristate acetate-induced Egr-1 expression is suppressed by phospholipase D isozymes in human glioma cells.
Neoplasms
Phosphatidic Acid Increases Epidermal Growth Factor Receptor Expression by Stabilizing mRNA Decay and by Inhibiting Lysosomal and Proteasomal Degradation of the Internalized Receptor.
Neoplasms
Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells.
Neoplasms
Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model.
Neoplasms
Phospholipase D activation in human natural killer cells through the Kp43 and CD16 surface antigens takes place by different mechanisms. Involvement of the phospholipase D pathway in tumor necrosis factor alpha synthesis.
Neoplasms
Phospholipase D activation mediates growth and migration of colon cancer cells interacting with cancer-associated fibroblasts.
Neoplasms
Phospholipase D activity is elevated in hepatitis C virus core protein-transformed NIH3T3 mouse fibroblast cells.
Neoplasms
Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets.
Neoplasms
Phospholipase D and the Mitogen Phosphatidic Acid in Human Disease: Inhibitors of PLD at the Crossroads of Phospholipid Biology and Cancer.
Neoplasms
Phospholipase D couples survival and migration signals in stress response of human cancer cells.
Neoplasms
Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.
Neoplasms
Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
Neoplasms
Phospholipase D inhibitors screening: Probing and evaluation of ancient and novel molecules.
Neoplasms
Phospholipase D Mediates Nutrient Input to Mammalian Target of Rapamycin Complex 1 (mTORC1).
Neoplasms
Phospholipase D mRNA expression and clinical role in high-grade serous carcinoma.
Neoplasms
Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10.
Neoplasms
Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.
Neoplasms
Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.
Neoplasms
Phospholipase D- and protein kinase C isoenzyme-dependent signal transduction pathways activated by the calcitonin receptor.
Neoplasms
Phospholipase D-mediated autophagic regulation is a potential target for cancer therapy.
Neoplasms
Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells.
Neoplasms
Phospholipase D1 Drives a Positive Feedback Loop to Reinforce the Wnt/{beta}-Catenin/TCF Signaling Axis.
Neoplasms
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Neoplasms
Phospholipase D1 is required for lipopolysaccharide-induced tumor necrosis factor-? expression and production through S6K1/JNK/c-Jun pathway in Raw 264.7 cells.
Neoplasms
Phospholipase D1-regulated autophagy supplies free fatty acids to counter nutrient stress in cancer cells.
Neoplasms
Phospholipase D2 loss results in increased blood pressure via inhibition of the endothelial nitric oxide synthase pathway.
Neoplasms
Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin.
Neoplasms
Phospholipid-modified upconversion nanoprobe for ratiometric fluorescence detection and imaging of phospholipase D in cell lysate and in living cells.
Neoplasms
Pivotal role of phospholipase D1 in tumor necrosis factor-?-mediated inflammation and scar formation after myocardial ischemia and reperfusion in mice.
Neoplasms
Plasma membrane homing of tissue nonspecific alkaline phosphatase under the influence of 3-hydrogenkwadaphnin, an antiproliferative agent from Dendrostellera lessertii.
Neoplasms
Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Neoplasms
Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFkappaB signaling pathway and enhances invasion of breast cancer cells.
Neoplasms
Platycodin D inhibits MPP+-induced inflammatory response in BV-2 cells through the TLR4/MyD88/NF-?B signaling pathway.
Neoplasms
PLD repair in rat rhabdomyosarcoma tumor cells irradiated in vivo and in vitro with high-LET and low-LET radiation.
Neoplasms
PLD-Specific Small-Molecule Inhibitors Decrease Tumor-Associated Macrophages and Neutrophils Infiltration in Breast Tumors and Lung and Liver Metastases.
Neoplasms
PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas.
Neoplasms
PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-?B signaling in bladder cancer.
Neoplasms
Polydatin ameliorates chemotherapy-induced cognitive impairment (chemobrain) by inhibiting oxidative stress, inflammatory response, and apoptosis in rats.
Neoplasms
Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells.
Neoplasms
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer.
Neoplasms
Potentially lethal damage repair as a possible determinant of human tumour radiosensitivity.
Neoplasms
Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Neoplasms
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Neoplasms
Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
Neoplasms
Primary angiosarcoma of the spleen, a rare indication for splenectomy: a case report.
Neoplasms
Procoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid.
Neoplasms
Profiling the relationship between tumor-associated macrophages and pharmacokinetics of liposomal agents in preclinical murine models.
Neoplasms
Proliferative and metastatic roles for Phospholipase D in mouse models of cancer.
Neoplasms
Prostate cancer-derived exosomes promote osteoblast differentiation and activity through phospholipase D2.
Neoplasms
Protective effect of platycodin D on liver injury in alloxan-induced diabetic mice via regulation of Treg/Th17 balance.
Neoplasms
Protein kinase C alpha associates with phospholipase D1 and enhances basal phospholipase D activity in a protein phosphorylation-independent manner in human melanoma cells.
Neoplasms
Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures.
Neoplasms
Pulsed-wave low-dose ultrasound hyperthermia selectively enhances nanodrug delivery and improves antitumor efficacy for brain metastasis of breast cancer.
Neoplasms
Pulsed-wave Ultrasound Hyperthermia Enhanced Nanodrug Delivery Combined with Chloroquine Exerts Effective Antitumor Response and Postpones Recurrence.
Neoplasms
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Neoplasms
Radiosensitizing effects of misonidazole and SR 2508 on a human melanoma transplanted in nude mice: influence on repair of potentially lethal damage.
Neoplasms
RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.
Neoplasms
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Neoplasms
Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NF?B and suppresses invasion of gastric cancer cells.
Neoplasms
Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.
Neoplasms
Recovery from potentially lethal damage after X-irradiation in three experimental tumors in mice.
Neoplasms
Release of gelatinase A (matrix metalloproteinase 2) induced by photolysis of caged phosphatidic acid in HT 1080 metastatic fibrosarcoma cells.
Neoplasms
Repair of potentially lethal and sublethal radiation damage in x-irradiated ascites tumor cells.
Neoplasms
Repair of potentially lethan radiation damage: comparison of neutron and X-ray RBE and implications for radiation therapy.
Neoplasms
Response of cells of human origin, normal and malignant, to acute and low dose rate irradiation.
Neoplasms
Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
Neoplasms
Role of phospholipase D in laminin-induced production of gelatinase A (MMP-2) in metastatic cells.
Neoplasms
Role of phospholipase D in migration and invasion induced by linoleic acid in breast cancer cells.
Neoplasms
Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion.
Neoplasms
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Neoplasms
SCD1 activity promotes cell migration via a PLD-mTOR pathway in the MDA-MB-231 triple-negative breast cancer cell line.
Neoplasms
Secretions of MMP-9 by soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) mediated by protein kinase C (PKC)delta and phospholipase D (PLD) in murine macrophage.
Neoplasms
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.
Neoplasms
Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Neoplasms
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Neoplasms
Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?
Neoplasms
Sustained PKC?II activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.
Neoplasms
Synergistic Effects of Nanodrug, Ultrasound Hyperthermia and Thermal Ablation on Solid Tumors - An Animal Study.
Neoplasms
Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Neoplasms
Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells.
Neoplasms
Tanshinone II improves distribution and anti-tumor efficacy of pegylated liposomal doxorubicin via normalizing the structure and function of tumor vasculature in hepa1-6 hepatoma mice model.
Neoplasms
Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis.
Neoplasms
Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Neoplasms
Temporal production of the signaling lipid phosphatidic acid by phospholipase D2 determines the output of extracellular signal-regulated kinase signaling in cancer cells.
Neoplasms
The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience.
Neoplasms
The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Neoplasms
The importance of G1/S-border and mitosis in the fixation of potentially lethal damage.
Neoplasms
The influence of PLD repair on the induction frequency of 6-thioguanine resistant mutants in Ehrlich ascites tumour cells after exposure to X-rays and ultraviolet light.
Neoplasms
The Mount Sinai experience with orthotopic liver transplantation for benign tumors: brief report and literature review: case reports.
Neoplasms
The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction.
Neoplasms
The radiation response of V79 and human tumour multicellular spheroids--cell survival and growth delay studies.
Neoplasms
The role in cancer therapy of inhibiting recovery from PLD induced by radiation or bleomycin.
Neoplasms
The transcription factors Slug (SNAI2) and Snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion.
Neoplasms
The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
Neoplasms
Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Neoplasms
Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: Comparing single and combined therapy in young and old mice.
Neoplasms
Tissue microarray staining reveals PLD1 and Sp1 have a collaborative, pro-tumoral effect in patients with osteosarcomas.
Neoplasms
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Neoplasms
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.
Neoplasms
Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment.
Neoplasms
Tumor kinetics and timing of the second dose to improve tumor radiocurability--a prediction of the best timing for fractionation by measuring 125I-iododeoxyuridine uptake in situ.
Neoplasms
Tumor necrosis factor alpha priming of phospholipase D in human neutrophils. Correlation between phosphatidic acid production and superoxide generation.
Neoplasms
Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy.
Neoplasms
Tumour necrosis factor alpha potentiates ion secretion induced by histamine in a human intestinal epithelial cell line and in mouse colon: involvement of the phospholipase D pathway.
Neoplasms
Two sites of action for PLD2 inhibitors: The enzyme catalytic center and an allosteric, phosphoinositide biding pocket.
Neoplasms
Ultrasound sonication with microbubbles disrupts blood vessels and enhances tumor treatments of anticancer nanodrug.
Neoplasms
When spider and snake get along: Fusion of a snake disintegrin with a spider phospholipase D to explore their synergistic effects on a tumor cell.
Neoplasms
Wortmannin has opposite effects on phorbol ester-induced DNA synthesis and phosphatidylcholine hydrolysis.
Neoplasms
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Neoplasms
[Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Neoplasms
[Mechanism of tumor cell invasion studied by a culture model--modification of invasiveness by host mediators]
Neoplasms
[The Effectiveness of Cooling Packaging Care in Relieving Chemotherapy-Induced Skin Toxicity Reactions in Cancer Patients Receiving Chemotherapy: A Systematic Review].
Neoplasms
[The experiment of pegylated liposomal doxorubicin to therapy tongue cancer and metastases lymph nodes]
Neoplasms
[Three-dimensional Pseudo-continuous Arterial Spin Label Non-contrast Enhanced Perfusion Imaging of Head and Neck Tumors with High-field MR System].
Neuritis
Increased expression of phospholipase D1 in the sciatic nerve of rats with experimental autoimmune neuritis.
Neuritis, Autoimmune, Experimental
Increased expression of phospholipase D1 in the sciatic nerve of rats with experimental autoimmune neuritis.
Neuroblastoma
Activation of phospholipase D by PKC and GTPgammaS in human neuroblastoma cells overexpressing MARCKS.
Neuroblastoma
Activation of phospholipase D in SH-SY5Y neuroblastoma cells: dependence on Ca2+ and protein kinase C.
Neuroblastoma
Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells.
Neuroblastoma
Ca2+ inhibits guanine nucleotide-activated phospholipase D in neural-derived NG108-15 cells.
Neuroblastoma
Characterization of phospholipase D activation by muscarinic receptors in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Evidence for a novel mechanism of activation of phospholipase D by endothelin-1 in neuroblastoma cells.
Neuroblastoma
Expression of MARCKS effector domain mutants alters phospholipase D activity and cytoskeletal morphology of SK-N-MC neuroblastoma cells.
Neuroblastoma
Involvement of diacylglycerol produced by phospholipase D activation in A?-induced reduction of sAPP? secretion in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Overexpression of myristoylated alanine-rich C-kinase substrate enhances activation of phospholipase D by protein kinase C in SK-N-MC human neuroblastoma cells.
Neuroblastoma
Phosphatidic acid activation of protein kinase C in LA-N-1 neuroblastoma cells.
Neuroblastoma
Phosphatidylethanol biosynthesis in ethanol-exposed NG108-15 neuroblastoma X glioma hybrid cells. Evidence for activation of a phospholipase D phosphatidyl transferase activity by protein kinase C.
Neuroblastoma
Phospholipase D and phospholipase C in human cholinergic neuroblastoma (LA-N-2) cells: modulation by muscarinic agonists and protein kinase C.
Neuroblastoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Neuroblastoma
Retinoic acid specifically activates an oleate-dependent phospholipase D in the nuclei of LA-N-1 neuroblastoma cells.
Neuroblastoma
Stimulation of phospholipase D activity in human neuroblastoma (LA-N-2) cells by activation of muscarinic acetylcholine receptors or by phorbol esters: relationship to phosphoinositide turnover.
Neurodegenerative Diseases
alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.
Neurodegenerative Diseases
It Is Not Just in Faces! Processing of Emotion and Intention from Biological Motion in Psychiatric Disorders.
Neurodegenerative Diseases
NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes.
Neurodegenerative Diseases
Targeting phospholipase D in cancer, infection and neurodegenerative disorders.
Neurodegenerative Diseases
Using Drosophila melanogaster To Discover Human Disease Genes: An Educational Primer for Use with "Amyotrophic Lateral Sclerosis Modifiers in Drosophila Reveal the Phospholipase D Pathway as a Potential Therapeutic Target".
Neutropenia
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Neutropenia
Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.
Neutropenia
Liposomal anthracycline administration and toxicity management: a nursing perspective.
Neutropenia
Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
Neutropenia
Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin.
Neutropenia
Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer.
Neutropenia
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Neutropenia
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
Neutropenia
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Neutropenia
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Neutropenia
The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience.
Neutropenia
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.
Non-alcoholic Fatty Liver Disease
Hepatocellular Carcinoma in a Patient with Polycystic Liver Disease.
Non-alcoholic Fatty Liver Disease
Maternal obesity has sex-dependent effects on insulin, glucose and lipid metabolism and the liver transcriptome in young adult rat offspring.
Non-alcoholic Fatty Liver Disease
Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect.
Obesity
Adipose tissue NAPE-PLD controls fat mass development by altering the browning process and gut microbiota.
Obesity
Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis.
Obesity
Leptin increases TNF-? expression and production through phospholipase D1 in Raw 264.7 cells.
Obesity
LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.
Obesity
Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D.
Oligodendroglioma
Regulation of phospholipase D activity in a human oligodendroglioma cell line (HOG).
Osteoporosis
Does primary lactase deficiency reduce bone mineral density in postmenopausal women? A systematic review and meta-analysis.
Osteosarcoma
Cellular repair factors influencing radiocurability of human malignant tumours.
Osteosarcoma
MicroRNA-638 expression change in osteosarcoma patients via PLD1 and VEGF expression.
Osteosarcoma
Morphological effects of Pasteurella multocida type-D dermonecrotoxin on rat osteosarcoma cells in a nude mouse model.
Osteosarcoma
Proficient repair of potentially lethal damage sensitive to hypertonic treatment in osteosarcoma cells.
Osteosarcoma
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Osteosarcoma
Receptor-mediated binding of Pasteurella multocida dermonecrotic toxin to canine osteosarcoma and monkey kidney (vero) cells.
Osteosarcoma
Role of Phospholipase D in Parathyroid Hormone Type 1 Receptor Signaling and Trafficking.
Osteosarcoma
Role of protein kinase C alpha, Arf, and cytoplasmic calcium transients in phospholipase D activation by sodium fluoride in osteoblast-like cells.
Osteosarcoma
Tissue microarray staining reveals PLD1 and Sp1 have a collaborative, pro-tumoral effect in patients with osteosarcomas.
Osteosarcoma
[Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].
Otitis Externa
Genotyping and characterisation of the secretory lipolytic enzymes of Malassezia pachydermatis isolates collected from dogs.
Ovarian Neoplasms
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer.
Ovarian Neoplasms
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Ovarian Neoplasms
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Ovarian Neoplasms
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Ovarian Neoplasms
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Ovarian Neoplasms
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.
Ovarian Neoplasms
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Ovarian Neoplasms
Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: A Phase II study.
Ovarian Neoplasms
Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Ovarian Neoplasms
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
Ovarian Neoplasms
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Ovarian Neoplasms
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Ovarian Neoplasms
Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial.
Ovarian Neoplasms
Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer.
Ovarian Neoplasms
Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.
Ovarian Neoplasms
Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer.
Ovarian Neoplasms
Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
Ovarian Neoplasms
Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
Ovarian Neoplasms
Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers.
Ovarian Neoplasms
Clinical Risk Factors of PEGylated Liposomal Doxorubicin Induced Palmar Plantar Erythrodysesthesia in Recurrent Ovarian Cancer Patients.
Ovarian Neoplasms
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer.
Ovarian Neoplasms
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
Ovarian Neoplasms
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Ovarian Neoplasms
Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Ovarian Neoplasms
Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2.
Ovarian Neoplasms
Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial.
Ovarian Neoplasms
Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy.
Ovarian Neoplasms
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
Ovarian Neoplasms
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
Ovarian Neoplasms
Effect of BRCA1 and XPG Mutations on Treatment Response to Trabectedin and Pegylated Liposomal Doxorubicin in Patients with Advanced Ovarian Cancer - Exploratory Analysis of the Phase 3 OVA-301 Study.
Ovarian Neoplasms
Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.
Ovarian Neoplasms
Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
Ovarian Neoplasms
Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine.
Ovarian Neoplasms
Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Ovarian Neoplasms
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Ovarian Neoplasms
Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.
Ovarian Neoplasms
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
Ovarian Neoplasms
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
Ovarian Neoplasms
Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Ovarian Neoplasms
EPIDERMAL GROWTH FACTOR INCREASES LYSOPHOSPHATIDIC ACID PRODUCTION IN HUMAN OVARIAN CANCER CELLS: ROLES FOR PHOSPHOLIPASE D2 AND RECEPTOR TRANSACTIVATION.
Ovarian Neoplasms
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.
Ovarian Neoplasms
Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D.
Ovarian Neoplasms
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Ovarian Neoplasms
Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-Trial).
Ovarian Neoplasms
Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600?mg/m2 in recurrent ovarian cancer.
Ovarian Neoplasms
Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer.
Ovarian Neoplasms
Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
Ovarian Neoplasms
New developments in treatment of ovarian carcinoma: focus on trabectedin.
Ovarian Neoplasms
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Ovarian Neoplasms
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
Ovarian Neoplasms
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment.
Ovarian Neoplasms
Outcomes with Single Agent LIPO-DOX in Platinum-Resistant Ovarian and Fallopian Tube Cancers and Primary Peritoneal Adenocarcinoma - Chiang Mai University Hospital Experience.
Ovarian Neoplasms
Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone.
Ovarian Neoplasms
Pegylated liposomal doxorubicin (CAELYX((R))) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Ovarian Neoplasms
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Ovarian Neoplasms
Pegylated liposomal Doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase ib study.
Ovarian Neoplasms
Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate administration sequences.
Ovarian Neoplasms
Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer.
Ovarian Neoplasms
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
Ovarian Neoplasms
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
Ovarian Neoplasms
Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment.
Ovarian Neoplasms
Pharmacokinetics and efficacy of doxorubicin-loaded plant virus nanoparticles in preclinical models of cancer.
Ovarian Neoplasms
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Ovarian Neoplasms
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Ovarian Neoplasms
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
Ovarian Neoplasms
Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer.
Ovarian Neoplasms
Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
Ovarian Neoplasms
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Ovarian Neoplasms
Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
Ovarian Neoplasms
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Ovarian Neoplasms
Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Ovarian Neoplasms
Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer.
Ovarian Neoplasms
Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells.
Ovarian Neoplasms
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Ovarian Neoplasms
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Ovarian Neoplasms
Skin toxicity after palliative chemotherapy containing pegylated liposomal doxorubicin for ovarian cancer patients.
Ovarian Neoplasms
Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature.
Ovarian Neoplasms
Squamous Cell Carcinoma of the Oral Cavity in Nonsmoking Women: A New and Unusual Complication of Chemotherapy for Recurrent Ovarian Cancer?
Ovarian Neoplasms
Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
Ovarian Neoplasms
Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Ovarian Neoplasms
The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
Ovarian Neoplasms
The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Ovarian Neoplasms
The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Ovarian Neoplasms
The role of pegylated liposomal Doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.
Ovarian Neoplasms
TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
Ovarian Neoplasms
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Ovarian Neoplasms
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.
Ovarian Neoplasms
Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ovarian Neoplasms
Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Ovarian Neoplasms
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis.
Ovarian Neoplasms
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Ovarian Neoplasms
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Ovarian Neoplasms
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Ovarian Neoplasms
Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis.
Ovarian Neoplasms
Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Ovarian Neoplasms
Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
Pancreatitis
Dynamics of pancreatic tyrosine kinase and phospholipase D activities in the course of cerulein-induced acute pancreatitis and during regeneration.
Pancreatitis
The influence of polyamines synthesis inhibition on pancreas regeneration and phospholipase D activity after acute caerulein induced pancreatitis in rats. Biochemical and ultrastructural study.
Pancytopenia
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
Parkinson Disease
A protective role for N-acylphosphatidylethanolamine phospholipase D in 6-OHDA-induced neurodegeneration.
Parkinson Disease
alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells.
Parkinson Disease
NAPE-specific phospholipase D regulates LRRK2 association with neuronal membranes.
Parkinson Disease
Phospholipase D1 downregulation by ?-synuclein: Implications for neurodegeneration in Parkinson's disease.
Parkinson Disease
Platycodin D inhibits MPP+-induced inflammatory response in BV-2 cells through the TLR4/MyD88/NF-?B signaling pathway.
Parkinson Disease
The Lipase Activity of Phospholipase D2 is Responsible for Nigral Neurodegeneration in a Rat Model of Parkinson's Disease.
Pasteurellosis, Pneumonic
Role of phospholipase D in Pasteurella haemolytica leukotoxin-induced increase in phospholipase A(2) activity in bovine neutrophils.
Pemphigoid, Bullous
Differential display and cloning of the hippocampal gene mRNas in senescence accelerated mouse.
Pemphigus
Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in pemphigus IgG-induced signal transduction.
Periodontitis
Expression of Phospholipase D in Periodontitis and Its Role in the Inflammatory and Osteoclastic Response by Nicotine- and Lipopolysaccharide-Stimulated Human Periodontal Ligament Cells.
Peripheral Nervous System Diseases
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Peripheral Nervous System Diseases
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
Peripheral Nervous System Diseases
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer.
Peritonitis
Phospholipase D1 mediates TNFalpha-induced inflammation in a murine model of TNFalpha-induced peritonitis.
Persistent Infection
Inhibition of chlamydiae by primary alcohols correlates with the strain-specific complement of plasticity zone phospholipase D genes.
Persistent Infection
LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.
Pheochromocytoma
Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla.
Pheochromocytoma
Activation of phospholipase D is not mediated by direct phosphorylation on tyrosine residues.
Pheochromocytoma
ATP-induced mitogenesis is modulated by phospholipase D2 through extracellular signal regulated protein kinase dephosphorylation in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Bradykinin activates phospholipase D2 via protein kinase cdelta in PC12 cells.
Pheochromocytoma
Depolarization-induced differentiation of PC12 cells is mediated by phospholipase D2 through the transcription factor CREB pathway.
Pheochromocytoma
Enhancing effect of wortmannin on muscarinic stimulation of phospholipase D in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Hydrogen peroxide-induced phospholipase D activation in rat pheochromocytoma PC12 cells: possible involvement of Ca2+-dependent protein tyrosine kinase.
Pheochromocytoma
Implication of Ca(2+)-dependent protein tyrosine phosphorylation in carbachol-induced phospholipase D activation in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Implication of phospholipase D2 in oxidant-induced phosphoinositide 3-kinase signaling via Pyk2 activation in PC12 cells.
Pheochromocytoma
Involvement of ERK and p38 MAP kinase in oxidative stress-induced phospholipase D activation in PC12 cells.
Pheochromocytoma
Lysophosphatidylcholine suppresses apoptosis and induces neurite outgrowth in PC12 cells through activation of phospholipase D2.
Pheochromocytoma
Pertussis toxin-insensitive G protein mediates carbachol activation of phospholipase D in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Phospholipase D2 activity suppresses hydrogen peroxide-induced apoptosis in PC12 cells.
Pheochromocytoma
Phosphorylation-dependent regulation of phospholipase D2 by protein kinase C delta in rat Pheochromocytoma PC12 cells.
Pheochromocytoma
Possible involvement of mitogen-activated protein kinase in phospholipase D activation induced by H2O2, but not by carbachol, in rat pheochromocytoma PC12 cells.
Pheochromocytoma
Requirement of adenosine 5'-triphosphate and Ca2+ for guanosine 5'-triphosphate-binding protein-mediated phospholipase D activation in rat pheochromocytoma PC12 cells.
Pheochromocytoma
The inhibitory effect of local anesthetics on bradykinin-induced phospholipase D activation in rat pheochromocytoma PC12 cells.
phospholipase d deficiency
A role for Phospholipase D in Drosophila embryonic cellularization.
phospholipase d deficiency
Arabidopsis PLDzeta2 regulates vesicle trafficking and is required for auxin response.
phospholipase d deficiency
Differential Roles of Phospholipase D Proteins in Fc?RI-Mediated Signaling and Mast Cell Function.
phospholipase d deficiency
Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity.
phospholipase d deficiency
Phospholipase D1 deficiency in mice causes nonalcoholic fatty liver disease via an autophagy defect.
phospholipase d deficiency
Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid.
Plague
Structural organization of the pFra virulence-associated plasmid of rhamnose-positive Yersinia pestis.
Plague
[A comparative cytofluorimetric analysis of the blood leukocytes in guinea pigs exposed to the phospholipase D and antigens of the causative agent of plague]
Pleural Effusion
Laparoscopic treatment of simple hepatic cysts and polycystic liver disease.
Pleural Effusion
[A case of recurrent endometrial carcinoma with pleural effusion maintained long SD by pegylated liposomal doxorubicin(PLD)chemotherapy].
Pneumonia
Adenovirus-associated pneumonia in South African children: Presentation, clinical course and outcome.
Pneumonia
Corynebacterium ulcerans Isolated from an Asymptomatic Dog Kept in an Animal Shelter in the Metropolitan Area of Rio de Janeiro, Brazil.
Pneumonia
Role of phospholipase D in bleomycin-induced mitochondrial reactive oxygen species generation, mitochondrial DNA damage, and pulmonary fibrosis.
Pneumonia
Small protein A and phospholipase D immunization serves a protective role in a mouse pneumonia model of Acinetobacter baumannii infection.
Pneumonia
[The significance of the dermonecrotic toxin of P. multocida serovar D in the pathogenesis of pneumonia in swine]
Polycystic Kidney Diseases
Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation.
Polycystic Kidney Diseases
Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
Polycystic Kidney Diseases
Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
Polycystic Kidney Diseases
Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease.
Polycystic Kidney Diseases
Effects of Long-Term Exercise on Liver Cyst in Polycystic Liver Disease Model Rats.
Polycystic Kidney Diseases
Extended Liver Resection for Polycystic Liver Disease Can Challenge Liver Transplantation.
Polycystic Kidney Diseases
Ganab Haploinsufficiency Does Not Cause Polycystic Kidney Disease or Polycystic Liver Disease in Mice.
Polycystic Kidney Diseases
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
Polycystic Kidney Diseases
Laparoscopic cyst fenestration in the treatment of polycystic liver disease.
Polycystic Kidney Diseases
Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
Polycystic Kidney Diseases
Obstructive jaundice in a patient with polycystic liver disease complicated with polycystic kidney and polycystic lung: A case report.
Polycystic Kidney Diseases
Pancreatic ductal adenocarcinoma associated with Potter type III cystic disease.
Polycystic Kidney Diseases
Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation.
Polycystic Kidney Diseases
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
Polycystic Kidney Diseases
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Polycystic Kidney Diseases
Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values.
Polycystic Kidney Diseases
Results of percutaneous sclerotherapy and surgical treatment in patients with symptomatic simple liver cysts and polycystic liver disease.
Polycystic Kidney Diseases
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
Polycystic Kidney Diseases
The Role of Phospholipase D in Modulating the MTOR Signaling Pathway in Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation.
Polycystic Kidney, Autosomal Dominant
Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Combined liver and kidney transplant in a patient with budd-Chiari syndrome secondary to autosomal dominant polycystic kidney disease associated with polycystic liver disease: report of a case with a 9-year follow-up.
Polycystic Kidney, Autosomal Dominant
Comparison of volume-reductive therapies for massive polycystic liver disease in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Everolimus does not further reduce polycystic liver volume when added to long acting octreotide Results from a randomized controlled trial.
Polycystic Kidney, Autosomal Dominant
Fatal liver cyst rupture in polycystic liver disease complicated with autosomal dominant polycystic kidney disease: A case report.
Polycystic Kidney, Autosomal Dominant
Ganab Haploinsufficiency Does Not Cause Polycystic Kidney Disease or Polycystic Liver Disease in Mice.
Polycystic Kidney, Autosomal Dominant
Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.
Polycystic Kidney, Autosomal Dominant
IFT-A deficiency in juvenile mice impairs biliary development and exacerbates ADPKD liver disease.
Polycystic Kidney, Autosomal Dominant
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Polycystic Kidney, Autosomal Dominant
Isolated polycystic liver disease as a distinct genetic disease, unlinked to polycystic kidney disease 1 and polycystic kidney disease 2.
Polycystic Kidney, Autosomal Dominant
Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Polycystic Kidney, Autosomal Dominant
Novel GANAB variants associated with polycystic liver disease.
Polycystic Kidney, Autosomal Dominant
Pancreatic ductal adenocarcinoma associated with Potter type III cystic disease.
Polycystic Kidney, Autosomal Dominant
Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management.
Polycystic Kidney, Autosomal Dominant
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Polycystic Kidney, Autosomal Dominant
Prediction of hepatic cyst recurrence after minocycline hydrochloride aspiration sclerotherapy using cyst computed tomography values.
Polycystic Kidney, Autosomal Dominant
Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
Polycystic Kidney, Autosomal Dominant
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
Polycystic Kidney, Autosomal Dominant
Treatment of symptomatic polycystic liver disease: transcatheter super-selective hepatic arterial embolization using a mixture of NBCA and iodized oil.
Polycystic Kidney, Autosomal Dominant
Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
Polycystic Kidney, Autosomal Dominant
[Orthotopic liver transplantation in therapy of advanced polycystic liver disease]
Polycystic Kidney, Autosomal Recessive
Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management.
Polycythemia Vera
Defective neutrophil oxidative metabolism in polycythemia vera is associated with an impaired activation of phospholipase D.
Prediabetic State
MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: the KORA F4 study.
Pregnancy, Ectopic
Elevated anandamide and related N-acylethanolamine levels occur in the peripheral blood of women with ectopic pregnancy and are mirrored by changes in peripheral Fatty Acid amide hydrolase activity.
Prostatic Neoplasms
Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
Prostatic Neoplasms
Increased phospholipase D activity contributes to tumorigenesis in prostate cancer cell models.
Prostatic Neoplasms
Inhibition of Phospholipase D1 mRNA Expression Slows Down the Proliferation Rate of Prostate Cancer Cells That Have Transited to Androgen Independence.
Prostatic Neoplasms
Lysophosphatidic acid increases phosphatidic acid formation, phospholipase D activity and degranulation by human neutrophils.
Prostatic Neoplasms
Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells.
Prostatic Neoplasms
MicroRNA miR-145-5p inhibits Phospholipase D 5 (PLD5) to downregulate cell proliferation and metastasis to mitigate prostate cancer.
Prostatic Neoplasms
Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
Prostatic Neoplasms
Phospholipase D2 in prostate cancer: protein expression changes with Gleason score.
Prostatic Neoplasms
Tri-dimensional prostate cell cultures in simulated microgravity and induced changes in lipid second messengers and signal transduction.
Pulmonary Disease, Chronic Obstructive
Peripheral blood gene expression profiles in COPD subjects.
Pulmonary Disease, Chronic Obstructive
Six-Minute Walk Test in Chronic Respiratory Failure: Does Observed or Predictive Walk Distance Better Reflect Patient Functional Status?
Pulmonary Fibrosis
Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase d and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic Acid, in lung microvascular endothelial cells.
Pulmonary Fibrosis
Role of phospholipase D in bleomycin-induced mitochondrial reactive oxygen species generation, mitochondrial DNA damage, and pulmonary fibrosis.
Pulmonary Fibrosis
[Qingfeihuayutongfu prescription for intervening fibrosis in patients with sepsis-associated acute respiratory distress syndrome: a prospective single blind randomized controlled clinical trial study].
Renal Insufficiency
Developing recombinant phospholipase D1 (rPLD1) toxoid from Iranian Hemiscorpius lepturus scorpion and its protective effects in BALB/c mice.
Renal Insufficiency
Recent advances in the understanding of brown spider venoms: From the biology of spiders to the molecular mechanisms of toxins.
Renal Insufficiency
[Orthotopic liver transplantation in therapy of advanced polycystic liver disease]
Renal Insufficiency, Chronic
Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease.
Respiratory Distress Syndrome
Phospholipase D isoforms differentially regulate leukocyte responses to acute lung injury.
Respiratory Insufficiency
A case of pulmonary lymphoproliferative disorder presenting rapidly progressive respiratory failure.
Respiratory Insufficiency
[A case of AIDS-associated Kaposi's sarcoma with systemic invasion].
Retinal Degeneration
Dependence on the Lazaro phosphatidic acid phosphatase for the maximum light response.
Retinoblastoma
Repair of potentially lethal X-ray damage in fibroblasts derived from patients with hereditary and D-deletion retinoblastoma.
Rhabdomyosarcoma
PLD repair in rat rhabdomyosarcoma tumor cells irradiated in vivo and in vitro with high-LET and low-LET radiation.
Rhinitis
In vitro study of Pasteurella multocida adhesion to trachea, lung and aorta of rabbits.
Rhinitis, Atrophic
Association of Bordetella dermonecrotic toxin with the extracellular matrix.
Rhinitis, Atrophic
Clinical and pathological effects of the dermonecrotic toxin of Bordetella bronchiseptica and Pasteurella multocida in specific-pathogen-free piglets.
Rhinitis, Atrophic
Effects of sub-MICs of antibiotics on cell surface characteristics and virulence of Pasteurella multocida.
Rhinitis, Atrophic
Evaluation of an indirect enzyme-linked immunosorbent assay (ELISA) using recombinant toxin for detection of antibodies against Pasteurella multocida toxin.
Rhinitis, Atrophic
Induction of nasal turbinate atrophy in germ-free pigs, using Pasteurella multocida as well as bacterium-free crude and purified dermonecrotic toxin of P multocida.
Rhinitis, Atrophic
Polymorphisms Influencing Expression of Dermonecrotic Toxin in Bordetella bronchiseptica.
Rhinitis, Atrophic
Role of the dermonecrotic toxin of Bordetella bronchiseptica in the pathogenesis of respiratory disease in swine.
Rhinitis, Atrophic
Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida.
Rhinitis, Atrophic
Swine Atrophic Rhinitis Caused by Pasteurella multocida Toxin and Bordetella Dermonecrotic Toxin.
Sarcoma
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
Sarcoma
Effects of inhibitors of radiation-induced potentially lethal damage repair on chemotherapy in murine tumors.
Sarcoma
Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure.
Sarcoma
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Sarcoma
Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
Sarcoma
Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS).
Sarcoma
Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Sarcoma, Ewing
Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5' promoter.
Sarcoma, Ewing
Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.
Sarcoma, Kaposi
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
Sarcoma, Kaposi
Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients.
Sarcoma, Kaposi
Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors.
Sarcoma, Kaposi
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Sarcoma, Kaposi
Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
Sarcoma, Kaposi
Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review.
Sarcoma, Kaposi
The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction.
Scabies
Asymmetric in vitro synthesis of diastereomeric phosphatidylglycerols from phosphatidylcholine and glycerol by bacterial phospholipase D.
Scabies
Repeat-length-independent broad-spectrum shuffling, a novel method of generating a random chimera library in vivo.
Seizures
Differential expression of phospholipase D isozymes in the hippocampus following kainic acid-induced seizures.
Seizures
Lesion focused radiofrequency thermocoagulation of bottom-of-sulcus focal cortical dysplasia type IIb: Conceptional considerations with regard to the epileptogenic zone.
Sepsis
Enzymatic Activity Is Not Required for Phospholipase D Mediated TNF-? Regulation and Myocardial Healing.
Sepsis
Phospholipase D2 drives mortality in sepsis by inhibiting neutrophil extracellular trap formation and down-regulating CXCR2.
Sepsis
Procoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid.
Sepsis
Relationship between the diagnosis, preoperative evaluation, and prognosis after orthotopic liver transplantation.
Sepsis
VU0155069 inhibits inflammasome activation independent of phospholipase D1 activity.
Shock, Cardiogenic
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
Shock, Septic
Modulation of cyclooxygenase-2 expression by phosphatidylcholine specific phospholipase C and D in macrophages stimulated with lipopolysaccharide.
Skin Diseases
1,25-Dihydroxyvitamin D(3), phospholipase D and protein kinase C in keratinocyte differentiation.
Small Cell Lung Carcinoma
D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
Specific Language Disorder
[Procedural learning disorder: neuropsychological characteristics.]
Spondylitis, Ankylosing
Genome-wide DNA methylation analysis in ankylosing spondylitis identifies HLA-B*27 dependent and independent DNA methylation changes in whole blood.
Squamous Cell Carcinoma of Head and Neck
MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/?-catenin pathway by targeting phospholipase D1.
Starvation
A Repertoire of MicroRNAs Regulates Cancer Cell Starvation by Targeting Phospholipase D in a Feedback Loop That Operates Maximally in Cancer Cells.
Starvation
A specific variant of the PHR1 binding site is highly enriched in the Arabidopsis phosphate-responsive phospholipase DZ2 coexpression network.
Starvation
Drosophila Snazarus Regulates a Lipid Droplet Population at Plasma Membrane-Droplet Contacts in Adipocytes.
Starvation
How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD.
Starvation
Implication of phospholipase D in response of Hordeum vulgare root to short-term potassium deprivation.
Starvation
Increased phospholipase D activity contributes to tumorigenesis in prostate cancer cell models.
Starvation
Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors.
Starvation
Phospholipase DZ2 plays an important role in extraplastidic galactolipid biosynthesis and phosphate recycling in Arabidopsis roots.
Starvation
Quantitative profiling of Arabidopsis polar glycerolipids in response to phosphorus starvation. Roles of phospholipases D zeta1 and D zeta2 in phosphatidylcholine hydrolysis and digalactosyldiacylglycerol accumulation in phosphorus-starved plants.
Stomach Neoplasms
Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells.
Stomach Neoplasms
Rebamipide abolishes Helicobacter pylori CagA-induced phospholipase D1 expression via inhibition of NF?B and suppresses invasion of gastric cancer cells.
Stomach Neoplasms
Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.
Stomach Neoplasms
Src/ERK but not phospholipase D is involved in keratinocyte growth factor-stimulated secretion of matrix metalloprotease-9 and urokinase-type plasminogen activator in SNU-16 human stomach cancer cell.
Stomatitis
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Stomatitis
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Stomatitis
Liposomal anthracycline administration and toxicity management: a nursing perspective.
Stomatitis
Pegylated liposomal doxorubicin in elderly patients with metastatic breast cancer.
Stomatitis
Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Stomatitis
Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Stomatitis
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Stomatitis
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer.
Stomatitis
Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
Stomatitis
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.
Stomatitis
[Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Stroke
Peony and licorice decoction fumigation treatment for strephenopodia after stroke: Study protocol for a randomized controlled pilot trial.
Stroke
Perfusion and plaque evaluation to predict recurrent stroke in symptomatic middle cerebral artery stenosis.
Stroke
Portable Neuromonitoring Device Detects Large Vessel Occlusion in Suspected Acute Ischemic Stroke.
Stroke
The role of proximal body information on anticipatory judgment in tennis using graphical information richness.
Tangier Disease
Growth and cell cycle abnormalities of fibroblasts from Tangier disease patients.
Teratocarcinoma
Down-regulation of phospholipase D during differentiation of mouse F9 teratocarcinoma cells.
Thrombasthenia
Platelet phospholipase D is activated by protein kinase C via an integrin alpha IIb beta 3-independent mechanism.
Thrombocytopenia
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Thrombocytopenia
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
Thrombocytopenia
Recent advances in the understanding of brown spider venoms: From the biology of spiders to the molecular mechanisms of toxins.
Thrombocytopenia
The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials.
Thrombosis
Crystal structure of human PLD1 provides insight into activation by PI(4,5)P2 and RhoA.
Thrombosis
Enzymatic Activity Is Not Required for Phospholipase D Mediated TNF-? Regulation and Myocardial Healing.
Thrombosis
Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1.
Thrombosis
Pharmacological inhibition of phospholipase d protects mice from occlusive thrombus formation and ischemic stroke--brief report.
Thrombosis
Procoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid.
Thyroid Cancer, Papillary
Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
Thyroid Neoplasms
Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.
Tongue Neoplasms
[The experiment of pegylated liposomal doxorubicin to therapy tongue cancer and metastases lymph nodes]
Tonsillitis
[Detection of Arcanobacterium haemolyticum phospholipase D neutralizing antibodies in patients with acute tonsillitis]
Triple Negative Breast Neoplasms
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells.
Trypanosomiasis
Shedding light on lipid metabolism in Kinetoplastida: A phylogenetic analysis of phospholipase D protein homologs.
Tuberculosis
Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages.
Tuberculosis
ATP-induced killing of virulent Mycobacterium tuberculosis within human macrophages requires phospholipase D.
Tuberculosis
Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria.
Tuberculosis
CpG oligodeoxynucleotides promote phospholipase D dependent phagolysosome maturation and intracellular mycobacterial killing in M. tuberculosis infected type II alveolar epithelial cells.
Tuberculosis
Lysophosphatidic acid enhances antimycobacterial activity both in vitro and ex vivo.
Tuberous Sclerosis
Reciprocal Regulation of AMP-activated Protein Kinase and Phospholipase D.
Urinary Bladder Neoplasms
PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-?B signaling in bladder cancer.
Uterine Cervical Neoplasms
Promotion of cell autophagy and apoptosis in cervical cancer by inhibition of long noncoding RNA LINC00511 via transcription factor RXRA-regulated PLD1.
Vaccinia
A human homolog of the vaccinia virus HindIII K4L gene is a member of the phospholipase D superfamily.
Vaccinia
Expression of a novel murine phospholipase D homolog coincides with late neuronal development in the forebrain.
Vaccinia
Mutagenesis of phospholipase D defines a superfamily including a trans-Golgi viral protein required for poxvirus pathogenicity.
Vaccinia
Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D.
Vaginal Neoplasms
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
Vascular Calcification
Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease.
Vesicular Stomatitis
Arfaptin 1, an ARF-binding protein, inhibits phospholipase D and endoplasmic reticulum/Golgi protein transport.
Virus Diseases
Effect of Rho and ADP-ribosylation factor GTPases on phospholipase D activity in intact human adenocarcinoma A549 cells.
Virus Diseases
Enhancement of phospholipase D activity following baculovirus and adenovirus infection in Sf9 and COS-7 cells.
Virus Diseases
Pharmacophore modelling, virtual screening and molecular docking studies on PLD1 inhibitors.
Virus Diseases
The effect of mengovirus infection on lipid synthesis in cultured Ehrlich ascites tumor cells.
Whooping Cough
1,25-dihydroxyvitamin D3 but not TPA activates PLD in Caco-2 cells via pp60(c-src) and RhoA.
Whooping Cough
A protein kinase C inhibitor, staurosporine, activates phospholipase D via a pertussis toxin-sensitive GTP-binding protein in rabbit peritoneal neutrophils.
Whooping Cough
A tyrosine kinase regulates alpha-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta.
Whooping Cough
Abscisic acid stimulation of phospholipase D in the barley aleurone is G-protein-mediated and localized to the plasma membrane.
Whooping Cough
Activation of adenosine A1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells.
Whooping Cough
Activation of endothelial cell phospholipase D by sphingosine and sphingosine-1-phosphate.
Whooping Cough
Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production.
Whooping Cough
Activation of phospholipase C and phospholipase D by stimulation of adenosine A1, bradykinin or P2U receptors does not correlate well with protein kinase C activation.
Whooping Cough
Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells.
Whooping Cough
Activation of phospholipase D in rabbit neutrophils by fMet-Leu-Phe is mediated by a pertussis toxin-sensitive GTP-binding protein that may be distinct from a phospholipase C-regulating protein.
Whooping Cough
ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils.
Whooping Cough
Agonist-mediated downregulation of G alpha i via the alpha 2-adrenergic receptor is targeted by receptor-Gi interaction and is independent of receptor signaling and regulation.
Whooping Cough
Alpha 2-C10 adrenergic receptors expressed in rat 1 fibroblasts can regulate both adenylylcyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins.
Whooping Cough
Angiotensin II receptor coupling to phospholipase D is mediated by the betagamma subunits of heterotrimeric G proteins in vascular smooth muscle cells.
Whooping Cough
Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
Whooping Cough
Attenuated Bordetella pertussis Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced Migration and Drives a Th1/Th17 Response.
Whooping Cough
Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Whooping Cough
Bordetella Dermonecrotic Toxin Is a Neurotropic Virulence Factor That Uses CaV3.1 as the Cell Surface Receptor.
Whooping Cough
Bordetella dermonecrotic toxin undergoes proteolytic processing to be translocated from a dynamin-related endosome into the cytoplasm in an acidification-independent manner.
Whooping Cough
Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity.
Whooping Cough
Bordetella pertussis virulence factors affect phagocytosis by human neutrophils.
Whooping Cough
Bordetella pertussis, the Causative Agent of Whooping Cough, Evolved from a Distinct, Human-Associated Lineage of B. bronchiseptica.
Whooping Cough
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins.
Whooping Cough
Chemoattractant receptor-specific differences in G protein activation rates regulate effector enzyme and functional responses.
Whooping Cough
Cloning, expression, and molecular characterization of the dermonecrotic toxin gene of Bordetella spp.
Whooping Cough
Compound 48/80 activates mast cell phospholipase D via heterotrimeric GTP-binding proteins.
Whooping Cough
Crystal-induced neutrophil activation. II. Evidence for the activation of a phosphatidylcholine-specific phospholipase D.
Whooping Cough
D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
Whooping Cough
D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway.
Whooping Cough
D3 dopamine receptor signals to activation of phospholipase D through a complex with Rho.
Whooping Cough
Dermonecrotic toxin and tracheal cytotoxin, putative virulence factors of Bordetella avium.
Whooping Cough
Development of a targeted nanoLC-MS/MS method for quantitation of residual toxins from Bordetella pertussis.
Whooping Cough
Differential phospholipase D activation by bradykinin and sphingosine 1-phosphate in NIH 3T3 fibroblasts overexpressing gelsolin.
Whooping Cough
Direct relationship between intracellular calcium mobilization and phospholipase D activation in prostaglandin E-stimulated human erythroleukemia cells.
Whooping Cough
Effect of dermonecrotic toxin of Bordetella pertussis on the spleen of CFW and C57BL/10ScN mice.
Whooping Cough
Effect of lymphocytosis-promoting factor from Bordetella pertussis on cerebellar cyclic GMP levels.
Whooping Cough
Effect of prostaglandin E2 on phospholipase D activity in osteoblast-like MC3T3-E1 cells.
Whooping Cough
Effect of retinoic acid on prostaglandin F2 alpha-induced phospholipase D activity in osteoblast-like cells.
Whooping Cough
Effects of human low-density lipoproteins on superoxide production by formyl-methionyl-leucyl-phenylalanine activated polymorphonuclear leukocytes.
Whooping Cough
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Whooping Cough
Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Whooping Cough
Granulocyte-macrophage colony-stimulating factor primes phospholipase D activity in human neutrophils in vitro: role of calcium, G-proteins and tyrosine kinases.
Whooping Cough
Growth and cell cycle abnormalities of fibroblasts from Tangier disease patients.
Whooping Cough
Guanine nucleotide-binding protein regulation of microsomal phospholipase D activity of canine cerebral cortex.
Whooping Cough
Insulin-stimulated phosphatidylcholine hydrolysis, diacylglycerol/protein kinase C signalling, and hexose transport in pertussis toxin-treated BC3H-1 myocytes.
Whooping Cough
Intracellular localization of the dermonecrotic toxin of Bordetella pertussis.
Whooping Cough
LysoPC and PAF Trigger Arachidonic Acid Release by Divergent Signaling Mechanisms in Monocytes.
Whooping Cough
Lysophosphatidic acid activation of phosphatidylcholine-hydrolysing phospholipase D and actin polymerization by a pertussis toxin-sensitive mechanism.
Whooping Cough
Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells.
Whooping Cough
Mastoparan-induced phosphatidylcholine hydrolysis by phospholipase D activation in human astrocytoma cells.
Whooping Cough
Mechanical stimulation of skeletal muscle increases prostaglandin F2 alpha production, cyclooxygenase activity, and cell growth by a pertussis toxin sensitive mechanism.
Whooping Cough
Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains.
Whooping Cough
Novel model of integration of signaling pathways in rat pancreatic acinar cells.
Whooping Cough
Ontogenetic and pharmacological studies on metabotropic glutamate receptors coupled to phospholipase D activation.
Whooping Cough
Pertussis toxin-insensitive G protein mediates carbachol activation of phospholipase D in rat pheochromocytoma PC12 cells.
Whooping Cough
Phase variation in Bordetella pertussis by frameshift mutation in a gene for a novel two-component system.
Whooping Cough
Phospholipase C and phospholipase D are activated independently of each other in chemotactic peptide-stimulated human neutrophils.
Whooping Cough
Phospholipase C, protein kinase C, Ca(2+)/calmodulin-dependent protein kinase II, and tyrosine phosphorylation are involved in carbachol-induced phospholipase D activation in Chinese hamster ovary cells expressing muscarinic acetylcholine receptor of Caenorhabditis elegans.
Whooping Cough
Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits.
Whooping Cough
Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells.
Whooping Cough
Phospholipase D activity in PC12 cells. Effects of overexpression of alpha2A-adrenergic receptors.
Whooping Cough
Phospholipase D from photoreceptor rod outer segments is a downstream effector of RhoA: evidence of a light-dependent mechanism.
Whooping Cough
Phospholipase D is activated by G protein and not by calcium ions in vascular smooth muscle.
Whooping Cough
Phospholipase D1 is threonine-phosphorylated in human-airway epithelial cells stimulated by sphingosine-1-phosphate by a mechanism involving Src tyrosine kinase and protein kinase Cdelta.
Whooping Cough
Production of Highly Active Recombinant Dermonecrotic Toxin of Bordetella Pertussis.
Whooping Cough
Protein kinase C-dependent coupling of alpha(2A/D)-adrenergic receptors to phospholipase D.
Whooping Cough
Regulation of phospholipase D (PLD) in growth plate chondrocytes by 24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells) and is specific to the PLD2 isoform.
Whooping Cough
Regulation of phospholipase D and primary granule secretion by P2-purinergic- and chemotactic peptide-receptor agonists is induced during granulocytic differentiation of HL-60 cells.
Whooping Cough
Sensitization of human neutrophil defense activities through activation of platelet-activating factor receptors by ginkgolide B, a bioactive component of the Ginkgo biloba extract EGB 761.
Whooping Cough
Signalling components involved in the coupling of alpha 1-adrenoceptors to phospholipase D in neonatal rat cardiac myocytes.
Whooping Cough
Sphingosine-1-phosphate activates phospholipase D in human airway epithelial cells via a G protein-coupled receptor.
Whooping Cough
Sphingosine-1-phosphate increases human alveolar epithelial IL-8 secretion, proliferation and neutrophil chemotaxis.
Whooping Cough
Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages.
Whooping Cough
Stimulation of reactive oxidant production in neutrophils by soluble and insoluble immune complexes occurs via different receptors/signal transduction systems.
Whooping Cough
Surface proteins of Bordetella pertussis: comparison of virulent and avirulent strains and effects of phenotypic modulation.
Whooping Cough
The Ca2+-sensing receptor couples to Galpha12/13 to activate phospholipase D in Madin-Darby canine kidney cells.
Whooping Cough
The H1 receptor agonist 2-(3-chlorophenyl)histamine activates Gi proteins in HL-60 cells through a mechanism that is independent of known histamine receptor subtypes.
Whooping Cough
The M3 muscarinic acetylcholine receptor expressed in HEK-293 cells signals to phospholipase D via G12 but not Gq-type G proteins: regulators of G proteins as tools to dissect pertussis toxin-resistant G proteins in receptor-effector coupling.
Whooping Cough
The priming effect of 12(S)-hydroxyeicosatetraenoic acid on lymphocyte phospholipase D involves specific binding sites.
Whooping Cough
Thrombin stimulation of human endothelial cell phospholipase D activity. Regulation by phospholipase C, protein kinase C, and cyclic adenosine 3'5'-monophosphate.
Whooping Cough
Upregulation of macrophage plasma membrane and nuclear phospholipase D activity on ligation of the alpha2-macroglobulin signaling receptor: involvement of heterotrimeric and monomeric G proteins.
Whooping Cough
Vasopressin activates phospholipase D through pertussis toxin-insensitive GTP-binding protein in aortic smooth muscle cells: function of Ca2+/calmodulin.
Whooping Cough
[Construction of the genetically attenuated bacteria Aordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form]
Whooping Cough
[Immunobiologic activity of Bordetella pertussis strains defective in various virulence factors]
Wiskott-Aldrich Syndrome
A novel phospholipase D2-Grb2-WASp heterotrimer regulates leukocyte phagocytosis in a two-step mechanism.
Wiskott-Aldrich Syndrome
Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
physiological function
Q13393, Q14939
reconstitution of human PLD2 is only partly able to rescue retinal degeneration in a loss of function Drosophila PLD mutant. PLD2 is unable to restore the levels of a subset of unique species of phosphatidic acid in Drosophila. Contrary to the Drosophila enzyme, isoform PLD2 does not localize with subplasma membrane actin
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Panda, A.; Thakur, R.; Krishnan, H.; Naik, A.; Shinde, D.; Raghu, P.
Functional analysis of mammalian phospholipase D enzymes
Biosci. Rep.
38
BSR20181690
2018
Homo sapiens (Q13393), Homo sapiens (Q14939), Homo sapiens
brenda
EXTERNAL LINKS (specific for EC-Number 3.1.4.4)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
